The  ||| S:24 E:28 ||| DT
problem  ||| S:28 E:44 ||| NN
Three  ||| S:44 E:50 ||| CD
published  ||| S:50 E:60 ||| NNS
[  ||| S:60 E:62 ||| -LRB-
1  ||| S:62 E:64 ||| CD
2  ||| S:64 E:66 ||| CD
3  ||| S:66 E:68 ||| CD
]  ||| S:68 E:70 ||| -RRB-
and  ||| S:70 E:74 ||| CC
one  ||| S:74 E:78 ||| CD
recently  ||| S:78 E:87 ||| RB
presented  ||| S:87 E:97 ||| VBN
[  ||| S:97 E:99 ||| -LRB-
4  ||| S:99 E:109 ||| LS
]  ||| S:109 E:111 ||| -RRB-
randomized  ||| S:111 E:122 ||| JJ
placebo-controlled  ||| S:122 E:141 ||| JJ
clinical  ||| S:141 E:150 ||| JJ
trial  ||| S:150 E:156 ||| NN
have  ||| S:156 E:169 ||| VBP
unequivocally  ||| S:169 E:183 ||| RB
demonstrated  ||| S:183 E:196 ||| VBN
that  ||| S:196 E:201 ||| IN
3-Hydroxy-3-methylgluatryl  ||| S:201 E:236 ||| NNP
coenzyme  ||| S:236 E:245 ||| VBD
A  ||| S:245 E:247 ||| DT
( ||| S:247 E:248 ||| -LRB-
HMG  ||| S:248 E:252 ||| NNP
CoA ||| S:252 E:255 ||| NNP
)  ||| S:255 E:257 ||| -RRB-
reductase  ||| S:257 E:267 ||| FW
inhibitors  ||| S:267 E:278 ||| FW
( ||| S:278 E:279 ||| -LRB-
statins ||| S:279 E:286 ||| LS
)  ||| S:286 E:288 ||| -RRB-
reduce  ||| S:288 E:303 ||| VB
the  ||| S:303 E:307 ||| DT
morbidity  ||| S:307 E:317 ||| NN
and  ||| S:317 E:321 ||| CC
mortality  ||| S:321 E:331 ||| NN
associated  ||| S:331 E:342 ||| VBN
with  ||| S:342 E:347 ||| IN
coronary  ||| S:347 E:364 ||| JJ
disease ||| S:364 E:371 ||| NN
.  ||| S:371 E:373 ||| .
These  ||| S:373 E:379 ||| DT
trials  ||| S:379 E:386 ||| NNS
found  ||| S:386 E:392 ||| VBD
that  ||| S:392 E:397 ||| IN
when  ||| S:397 E:402 ||| WRB
compared  ||| S:402 E:411 ||| VBN
with  ||| S:411 E:424 ||| IN
placebo ||| S:424 E:431 ||| NN
,  ||| S:431 E:433 ||| ,
statins  ||| S:433 E:441 ||| VBD
significantly  ||| S:441 E:455 ||| RB
reduced  ||| S:455 E:463 ||| VBN
the  ||| S:463 E:467 ||| DT
incidence  ||| S:467 E:477 ||| NN
of  ||| S:477 E:488 ||| IN
death ||| S:488 E:493 ||| NN
,  ||| S:493 E:495 ||| ,
myocardial  ||| S:495 E:506 ||| JJ
infarction ||| S:506 E:516 ||| NN
,  ||| S:516 E:518 ||| ,
unstable  ||| S:518 E:527 ||| JJ
angina ||| S:527 E:533 ||| NN
,  ||| S:533 E:535 ||| ,
percutaneous  ||| S:535 E:556 ||| NN
and  ||| S:556 E:560 ||| CC
surgical  ||| S:560 E:569 ||| JJ
coronary  ||| S:569 E:578 ||| JJ
revascularization ||| S:578 E:595 ||| NN
,  ||| S:595 E:597 ||| ,
and  ||| S:597 E:601 ||| CC
stroke  ||| S:601 E:608 ||| NN
in  ||| S:608 E:619 ||| IN
persons  ||| S:619 E:627 ||| NNS
with  ||| S:627 E:641 ||| IN
stable  ||| S:641 E:648 ||| JJ
coronary  ||| S:648 E:657 ||| JJ
disease ||| S:657 E:664 ||| NN
.  ||| S:664 E:666 ||| .
Because  ||| S:666 E:682 ||| IN
patients  ||| S:682 E:691 ||| NNS
who  ||| S:691 E:695 ||| WP
had  ||| S:695 E:699 ||| VBD
experienced  ||| S:699 E:711 ||| VBN
an  ||| S:711 E:714 ||| DT
acute  ||| S:714 E:720 ||| JJ
coronary  ||| S:720 E:729 ||| JJ
syndrome  ||| S:729 E:746 ||| NN
within  ||| S:746 E:753 ||| IN
three  ||| S:753 E:759 ||| CD
to  ||| S:759 E:762 ||| TO
six  ||| S:762 E:766 ||| CD
months  ||| S:766 E:773 ||| NNS
of  ||| S:773 E:776 ||| IN
enrollment  ||| S:776 E:787 ||| NN
were  ||| S:787 E:792 ||| VBD
excluded ||| S:792 E:800 ||| VBN
,  ||| S:800 E:810 ||| ,
these  ||| S:810 E:816 ||| DT
trials  ||| S:816 E:823 ||| NNS
did  ||| S:823 E:827 ||| VBD
not  ||| S:827 E:831 ||| RB
assess  ||| S:831 E:838 ||| VB
the  ||| S:838 E:842 ||| DT
effect  ||| S:842 E:849 ||| NN
of  ||| S:849 E:852 ||| IN
lipid-lowering  ||| S:852 E:875 ||| JJ
therapy  ||| S:875 E:883 ||| NN
on  ||| S:883 E:886 ||| IN
adverse  ||| S:886 E:894 ||| JJ
cardiovascular  ||| S:894 E:909 ||| JJ
events  ||| S:909 E:916 ||| NNS
in  ||| S:916 E:919 ||| IN
those  ||| S:919 E:925 ||| DT
with  ||| S:925 E:938 ||| IN
recently  ||| S:938 E:956 ||| RB
unstable  ||| S:956 E:965 ||| JJ
coronary  ||| S:965 E:974 ||| JJ
disease ||| S:974 E:981 ||| NN
.  ||| S:981 E:983 ||| .
Whether  ||| S:983 E:999 ||| IN
lipid-lowering  ||| S:999 E:1014 ||| JJ
therapy  ||| S:1014 E:1022 ||| NN
would  ||| S:1022 E:1028 ||| MD
provide  ||| S:1028 E:1036 ||| VB
incremental  ||| S:1036 E:1048 ||| JJ
benefit  ||| S:1048 E:1056 ||| NN
if  ||| S:1056 E:1067 ||| IN
initiated  ||| S:1067 E:1077 ||| VBN
immediately  ||| S:1077 E:1089 ||| RB
following  ||| S:1089 E:1099 ||| VBG
an  ||| S:1099 E:1102 ||| DT
acute  ||| S:1102 E:1108 ||| JJ
coronary  ||| S:1108 E:1117 ||| JJ
syndrome  ||| S:1117 E:1134 ||| NN
is  ||| S:1134 E:1137 ||| VBZ
an  ||| S:1137 E:1140 ||| DT
important  ||| S:1140 E:1150 ||| JJ
issue  ||| S:1150 E:1156 ||| NN
as  ||| S:1156 E:1159 ||| IN
the  ||| S:1159 E:1163 ||| DT
risk  ||| S:1163 E:1168 ||| NN
of  ||| S:1168 E:1171 ||| IN
a  ||| S:1171 E:1173 ||| DT
recurrent  ||| S:1173 E:1183 ||| JJ
adverse  ||| S:1183 E:1199 ||| JJ
cardiac  ||| S:1199 E:1207 ||| JJ
events  ||| S:1207 E:1214 ||| NNS
is  ||| S:1214 E:1217 ||| VBZ
much  ||| S:1217 E:1222 ||| RB
greater  ||| S:1222 E:1230 ||| JJR
in  ||| S:1230 E:1233 ||| IN
patients  ||| S:1233 E:1242 ||| NNS
with  ||| S:1242 E:1247 ||| IN
unstable  ||| S:1247 E:1264 ||| JJ
coronary  ||| S:1264 E:1273 ||| JJ
disease  ||| S:1273 E:1281 ||| NN
than  ||| S:1281 E:1286 ||| IN
in  ||| S:1286 E:1289 ||| IN
the  ||| S:1289 E:1293 ||| DT
stable  ||| S:1293 E:1300 ||| JJ
setting ||| S:1300 E:1307 ||| NN
.  ||| S:1307 E:1309 ||| .
The  ||| S:1309 E:1313 ||| DT
Myocardial  ||| S:1313 E:1332 ||| NNP
Ischemia  ||| S:1332 E:1341 ||| NNP
Reduction  ||| S:1341 E:1351 ||| NNP
with  ||| S:1351 E:1356 ||| IN
Aggressive  ||| S:1356 E:1367 ||| NNP
Cholesterol  ||| S:1367 E:1379 ||| NNP
Lowering  ||| S:1379 E:1396 ||| NNP
( ||| S:1396 E:1397 ||| -LRB-
MIRACL ||| S:1397 E:1403 ||| NNP
)  ||| S:1403 E:1405 ||| -RRB-
trial  ||| S:1405 E:1411 ||| NN
set  ||| S:1411 E:1415 ||| VBN
out  ||| S:1415 E:1419 ||| RP
to  ||| S:1419 E:1422 ||| TO
answer  ||| S:1422 E:1429 ||| VB
this  ||| S:1429 E:1434 ||| DT
question ||| S:1434 E:1442 ||| NN
.  ||| S:1442 E:1466 ||| .
The  ||| S:1466 E:1470 ||| DT
answer ||| S:1470 E:1476 ||| NN
?  ||| S:1476 E:1486 ||| .
MIRACL  ||| S:1486 E:1493 ||| NNP
enrolled  ||| S:1493 E:1502 ||| VBD
3,086  ||| S:1502 E:1508 ||| CD
patients  ||| S:1508 E:1517 ||| NNS
within  ||| S:1517 E:1524 ||| IN
24-96  ||| S:1524 E:1530 ||| CD
hours  ||| S:1530 E:1536 ||| NNS
( ||| S:1536 E:1537 ||| -LRB-
mean  ||| S:1537 E:1550 ||| VB
63  ||| S:1550 E:1553 ||| CD
hours ||| S:1553 E:1558 ||| NNS
)  ||| S:1558 E:1560 ||| -RRB-
of  ||| S:1560 E:1563 ||| IN
admission  ||| S:1563 E:1573 ||| NN
for  ||| S:1573 E:1577 ||| IN
unstable  ||| S:1577 E:1586 ||| JJ
angina  ||| S:1586 E:1593 ||| NN
or  ||| S:1593 E:1596 ||| CC
a  ||| S:1596 E:1598 ||| DT
non-Q-wave  ||| S:1598 E:1617 ||| JJ
myocardial  ||| S:1617 E:1628 ||| JJ
infarction  ||| S:1628 E:1639 ||| NN
and  ||| S:1639 E:1643 ||| CC
randomized  ||| S:1643 E:1654 ||| VBD
them  ||| S:1654 E:1659 ||| PRP
to  ||| S:1659 E:1662 ||| TO
16  ||| S:1662 E:1665 ||| CD
weeks  ||| S:1665 E:1671 ||| NNS
of  ||| S:1671 E:1682 ||| IN
atorvastatin  ||| S:1682 E:1695 ||| CD
80  ||| S:1695 E:1698 ||| CD
mg  ||| S:1698 E:1701 ||| NNS
or  ||| S:1701 E:1704 ||| CC
placebo  ||| S:1704 E:1712 ||| VBP
once  ||| S:1712 E:1717 ||| RB
daily  ||| S:1717 E:1723 ||| JJ
[  ||| S:1723 E:1725 ||| -LRB-
5  ||| S:1725 E:1727 ||| LS
]  ||| S:1727 E:1729 ||| -RRB-
.  ||| S:1729 E:1731 ||| .
The  ||| S:1731 E:1735 ||| DT
major  ||| S:1735 E:1749 ||| JJ
exclusion  ||| S:1749 E:1759 ||| NN
criteria  ||| S:1759 E:1768 ||| NNS
were ||| S:1768 E:1772 ||| VBD
:  ||| S:1772 E:1774 ||| :
total  ||| S:1774 E:1780 ||| JJ
cholesterol  ||| S:1780 E:1792 ||| NN
level  ||| S:1792 E:1798 ||| NN
greater  ||| S:1798 E:1814 ||| JJR
than  ||| S:1814 E:1819 ||| IN
270  ||| S:1819 E:1823 ||| CD
mg ||| S:1823 E:1825 ||| CD
/ ||| S:1825 E:1826 ||| CD
dL ||| S:1826 E:1828 ||| NN
;  ||| S:1828 E:1830 ||| :
Q-wave  ||| S:1830 E:1837 ||| JJ
myocardial  ||| S:1837 E:1848 ||| JJ
infarction  ||| S:1848 E:1859 ||| NN
on  ||| S:1859 E:1862 ||| IN
admission  ||| S:1862 E:1880 ||| NN
or  ||| S:1880 E:1883 ||| CC
during  ||| S:1883 E:1890 ||| IN
the  ||| S:1890 E:1894 ||| DT
previous  ||| S:1894 E:1903 ||| JJ
month ||| S:1903 E:1908 ||| NN
;  ||| S:1908 E:1910 ||| :
and ||| S:1910 E:1913 ||| CC
,  ||| S:1913 E:1915 ||| ,
coronary  ||| S:1915 E:1932 ||| JJ
revascularization  ||| S:1932 E:1950 ||| NN
in  ||| S:1950 E:1953 ||| IN
the  ||| S:1953 E:1957 ||| DT
months  ||| S:1957 E:1964 ||| NNS
before  ||| S:1964 E:1971 ||| IN
admission ||| S:1971 E:1980 ||| NN
,  ||| S:1980 E:1982 ||| ,
during  ||| S:1982 E:1997 ||| IN
the  ||| S:1997 E:2001 ||| DT
index  ||| S:2001 E:2007 ||| NN
hospitalization  ||| S:2007 E:2023 ||| NN
or  ||| S:2023 E:2026 ||| CC
anticipated  ||| S:2026 E:2038 ||| VBN
following  ||| S:2038 E:2048 ||| VBG
hospital  ||| S:2048 E:2065 ||| NN
discharge ||| S:2065 E:2074 ||| NN
.  ||| S:2074 E:2076 ||| .
The  ||| S:2076 E:2080 ||| DT
primary  ||| S:2080 E:2088 ||| JJ
efficacy  ||| S:2088 E:2097 ||| JJ
endpoint  ||| S:2097 E:2106 ||| NN
was  ||| S:2106 E:2110 ||| VBD
a  ||| S:2110 E:2112 ||| DT
composite  ||| S:2112 E:2122 ||| JJ
of  ||| S:2122 E:2133 ||| IN
death ||| S:2133 E:2138 ||| NN
,  ||| S:2138 E:2140 ||| ,
non-fatal  ||| S:2140 E:2150 ||| JJ
myocardial  ||| S:2150 E:2161 ||| JJ
infarction ||| S:2161 E:2171 ||| NN
,  ||| S:2171 E:2173 ||| ,
resuscitated  ||| S:2173 E:2186 ||| JJ
sudden  ||| S:2186 E:2201 ||| JJ
cardiac  ||| S:2201 E:2209 ||| JJ
death  ||| S:2209 E:2215 ||| NN
or  ||| S:2215 E:2218 ||| CC
emergent  ||| S:2218 E:2227 ||| JJ
rehospitalization  ||| S:2227 E:2245 ||| NN
for  ||| S:2245 E:2249 ||| IN
worsening  ||| S:2249 E:2267 ||| VBG
symptomatic  ||| S:2267 E:2279 ||| JJ
myocardial  ||| S:2279 E:2290 ||| JJ
ischemia ||| S:2290 E:2298 ||| NN
.  ||| S:2298 E:2300 ||| .
Secondary  ||| S:2300 E:2310 ||| JJ
endpoints  ||| S:2310 E:2328 ||| NN
included  ||| S:2328 E:2337 ||| VBD
stroke ||| S:2337 E:2343 ||| NN
,  ||| S:2343 E:2345 ||| ,
worsening  ||| S:2345 E:2355 ||| VBG
heart  ||| S:2355 E:2361 ||| NN
failure ||| S:2361 E:2368 ||| NN
,  ||| S:2368 E:2370 ||| ,
need  ||| S:2370 E:2375 ||| VBP
for  ||| S:2375 E:2379 ||| IN
coronary  ||| S:2379 E:2396 ||| JJ
revascularization  ||| S:2396 E:2414 ||| NN
and  ||| S:2414 E:2418 ||| CC
change  ||| S:2418 E:2425 ||| NN
in  ||| S:2425 E:2428 ||| IN
lipid  ||| S:2428 E:2434 ||| JJ
levels  ||| S:2434 E:2441 ||| NNS
throughout  ||| S:2441 E:2452 ||| IN
the  ||| S:2452 E:2464 ||| DT
study ||| S:2464 E:2469 ||| NN
.  ||| S:2469 E:2471 ||| .
On  ||| S:2471 E:2474 ||| IN
average ||| S:2474 E:2481 ||| NN
,  ||| S:2481 E:2483 ||| ,
patients  ||| S:2483 E:2492 ||| NNS
were  ||| S:2492 E:2497 ||| VBD
65  ||| S:2497 E:2500 ||| CD
years  ||| S:2500 E:2506 ||| NNS
of  ||| S:2506 E:2509 ||| IN
age ||| S:2509 E:2512 ||| NN
,  ||| S:2512 E:2522 ||| ,
approximately  ||| S:2522 E:2536 ||| RB
65 ||| S:2536 E:2538 ||| CD
%  ||| S:2538 E:2540 ||| NN
were  ||| S:2540 E:2545 ||| VBD
men ||| S:2545 E:2548 ||| NNS
,  ||| S:2548 E:2550 ||| ,
86 ||| S:2550 E:2552 ||| CD
%  ||| S:2552 E:2554 ||| NN
Caucasian  ||| S:2554 E:2564 ||| NNP
and  ||| S:2564 E:2568 ||| CC
the  ||| S:2568 E:2572 ||| DT
mean  ||| S:2572 E:2585 ||| JJ
baseline  ||| S:2585 E:2594 ||| NN
low  ||| S:2594 E:2598 ||| JJ
density  ||| S:2598 E:2606 ||| NN
lipoprotein  ||| S:2606 E:2618 ||| NNS
( ||| S:2618 E:2619 ||| -LRB-
LDL ||| S:2619 E:2622 ||| NNP
)  ||| S:2622 E:2624 ||| -RRB-
cholesterol  ||| S:2624 E:2636 ||| NN
level  ||| S:2636 E:2650 ||| NN
was  ||| S:2650 E:2654 ||| VBD
124  ||| S:2654 E:2658 ||| CD
mg ||| S:2658 E:2660 ||| CD
/ ||| S:2660 E:2661 ||| CD
dL ||| S:2661 E:2663 ||| NN
.  ||| S:2663 E:2665 ||| .
Atorvastatin  ||| S:2665 E:2678 ||| JJ
treatment  ||| S:2678 E:2688 ||| NN
was  ||| S:2688 E:2692 ||| VBD
associated  ||| S:2692 E:2703 ||| VBN
with  ||| S:2703 E:2708 ||| IN
a  ||| S:2708 E:2718 ||| DT
2.6 ||| S:2718 E:2721 ||| CD
%  ||| S:2721 E:2723 ||| NN
absolute  ||| S:2723 E:2732 ||| JJ
reduction  ||| S:2732 E:2742 ||| NN
in  ||| S:2742 E:2745 ||| IN
the  ||| S:2745 E:2749 ||| DT
risk  ||| S:2749 E:2754 ||| NN
of  ||| S:2754 E:2757 ||| IN
the  ||| S:2757 E:2761 ||| DT
primary  ||| S:2761 E:2769 ||| JJ
endpoint  ||| S:2769 E:2786 ||| NNS
( ||| S:2786 E:2787 ||| -LRB-
14.8 ||| S:2787 E:2791 ||| CD
%  ||| S:2791 E:2793 ||| NN
vs.  ||| S:2793 E:2797 ||| IN
17.4 ||| S:2797 E:2801 ||| CD
% ||| S:2801 E:2802 ||| NN
;  ||| S:2802 E:2804 ||| :
RR  ||| S:2804 E:2807 ||| NNP
relative  ||| S:2807 E:2816 ||| JJ
risk  ||| S:2816 E:2821 ||| NN
[ ||| S:2821 E:2822 ||| -LRB-
RR ||| S:2822 E:2824 ||| NNP
]  ||| S:2824 E:2826 ||| -RRB-
0.84 ||| S:2826 E:2830 ||| CD
,  ||| S:2830 E:2832 ||| ,
95 ||| S:2832 E:2834 ||| CD
%  ||| S:2834 E:2844 ||| NN
confidence  ||| S:2844 E:2855 ||| NN
interval  ||| S:2855 E:2864 ||| NNS
[ ||| S:2864 E:2865 ||| -LRB-
CI ||| S:2865 E:2867 ||| NNP
]  ||| S:2867 E:2869 ||| -RRB-
0.70-1.00 ||| S:2869 E:2878 ||| NNP
,  ||| S:2878 E:2880 ||| ,
p  ||| S:2880 E:2882 ||| VBG
=  ||| S:2882 E:2884 ||| SYM
0.048 ||| S:2884 E:2889 ||| CD
) ||| S:2889 E:2890 ||| -RRB-
.  ||| S:2890 E:2892 ||| .
This  ||| S:2892 E:2905 ||| DT
reduction  ||| S:2905 E:2915 ||| NN
was  ||| S:2915 E:2919 ||| VBD
primarily  ||| S:2919 E:2929 ||| RB
driven  ||| S:2929 E:2936 ||| VBN
by  ||| S:2936 E:2939 ||| IN
the  ||| S:2939 E:2943 ||| DT
2.2 ||| S:2943 E:2946 ||| CD
%  ||| S:2946 E:2948 ||| NN
absolute  ||| S:2948 E:2965 ||| JJ
reduction  ||| S:2965 E:2975 ||| NN
in  ||| S:2975 E:2978 ||| IN
incidence  ||| S:2978 E:2988 ||| NN
of  ||| S:2988 E:2991 ||| IN
emergent  ||| S:2991 E:3000 ||| JJ
rehospitalization  ||| S:3000 E:3018 ||| NN
for  ||| S:3018 E:3030 ||| IN
symptomatic  ||| S:3030 E:3042 ||| FW
myocardial  ||| S:3042 E:3053 ||| FW
ischemia  ||| S:3053 E:3062 ||| FW
( ||| S:3062 E:3063 ||| -LRB-
6.2 ||| S:3063 E:3066 ||| CD
%  ||| S:3066 E:3068 ||| NN
vs.  ||| S:3068 E:3072 ||| IN
8.4 ||| S:3072 E:3075 ||| CD
% ||| S:3075 E:3076 ||| NN
;  ||| S:3076 E:3078 ||| :
RR  ||| S:3078 E:3081 ||| NNP
0.74 ||| S:3081 E:3085 ||| NNP
,  ||| S:3085 E:3095 ||| ,
95 ||| S:3095 E:3097 ||| CD
%  ||| S:3097 E:3099 ||| NN
CI  ||| S:3099 E:3102 ||| NNP
0.57-0.95 ||| S:3102 E:3111 ||| NNP
,  ||| S:3111 E:3113 ||| ,
p  ||| S:3113 E:3115 ||| VBG
=  ||| S:3115 E:3117 ||| SYM
0.02 ||| S:3117 E:3121 ||| CD
) ||| S:3121 E:3122 ||| -RRB-
.  ||| S:3122 E:3124 ||| .
The  ||| S:3124 E:3128 ||| DT
risk  ||| S:3128 E:3133 ||| NN
of  ||| S:3133 E:3136 ||| IN
death ||| S:3136 E:3141 ||| NN
,  ||| S:3141 E:3143 ||| ,
nonfatal  ||| S:3143 E:3160 ||| FW
myocardial  ||| S:3160 E:3171 ||| FW
infarction  ||| S:3171 E:3182 ||| FW
and  ||| S:3182 E:3186 ||| CC
resuscitated  ||| S:3186 E:3199 ||| JJ
sudden  ||| S:3199 E:3206 ||| JJ
cardiac  ||| S:3206 E:3214 ||| JJ
death  ||| S:3214 E:3228 ||| NN
were  ||| S:3228 E:3233 ||| VBD
each  ||| S:3233 E:3238 ||| DT
no  ||| S:3238 E:3241 ||| DT
different  ||| S:3241 E:3251 ||| JJ
between  ||| S:3251 E:3259 ||| IN
the  ||| S:3259 E:3263 ||| DT
two  ||| S:3263 E:3267 ||| CD
groups ||| S:3267 E:3273 ||| NNS
.  ||| S:3273 E:3275 ||| .
While  ||| S:3275 E:3281 ||| IN
there  ||| S:3281 E:3295 ||| EX
were  ||| S:3295 E:3300 ||| VBD
no  ||| S:3300 E:3303 ||| DT
significant  ||| S:3303 E:3315 ||| JJ
differences  ||| S:3315 E:3327 ||| NNS
in  ||| S:3327 E:3330 ||| IN
the  ||| S:3330 E:3334 ||| DT
incidence  ||| S:3334 E:3344 ||| NN
of  ||| S:3344 E:3355 ||| IN
worsening  ||| S:3355 E:3365 ||| VBG
heart  ||| S:3365 E:3371 ||| NN
failure  ||| S:3371 E:3379 ||| NN
or  ||| S:3379 E:3382 ||| CC
need  ||| S:3382 E:3387 ||| NN
for  ||| S:3387 E:3391 ||| IN
coronary  ||| S:3391 E:3408 ||| JJ
revascularization ||| S:3408 E:3425 ||| NN
,  ||| S:3425 E:3427 ||| ,
atorvastatin  ||| S:3427 E:3440 ||| NN
did  ||| S:3440 E:3444 ||| VBD
reduce  ||| S:3444 E:3451 ||| VB
the  ||| S:3451 E:3455 ||| DT
incidence  ||| S:3455 E:3465 ||| NN
of  ||| S:3465 E:3476 ||| IN
fatal  ||| S:3476 E:3482 ||| JJ
or  ||| S:3482 E:3485 ||| CC
non-fatal  ||| S:3485 E:3495 ||| JJ
stroke  ||| S:3495 E:3502 ||| NN
by  ||| S:3502 E:3505 ||| IN
0.8 ||| S:3505 E:3508 ||| CD
%  ||| S:3508 E:3510 ||| NN
( ||| S:3510 E:3511 ||| -LRB-
0.8 ||| S:3511 E:3514 ||| CD
%  ||| S:3514 E:3516 ||| NN
vs.  ||| S:3516 E:3520 ||| IN
1.6 ||| S:3520 E:3523 ||| CD
% ||| S:3523 E:3524 ||| NN
;  ||| S:3524 E:3526 ||| :
RR  ||| S:3526 E:3529 ||| NNP
0.50 ||| S:3529 E:3533 ||| NNP
,  ||| S:3533 E:3543 ||| ,
95 ||| S:3543 E:3545 ||| CD
%  ||| S:3545 E:3547 ||| NN
CI  ||| S:3547 E:3550 ||| NNP
0.26-0.99 ||| S:3550 E:3559 ||| NNP
,  ||| S:3559 E:3561 ||| ,
p  ||| S:3561 E:3563 ||| VBG
=  ||| S:3563 E:3565 ||| SYM
0.045 ||| S:3565 E:3570 ||| CD
) ||| S:3570 E:3571 ||| -RRB-
.  ||| S:3571 E:3573 ||| .
Atorvastatin  ||| S:3573 E:3586 ||| NNP
also  ||| S:3586 E:3599 ||| RB
significantly  ||| S:3599 E:3613 ||| RB
reduced  ||| S:3613 E:3621 ||| VBN
total  ||| S:3621 E:3627 ||| JJ
and  ||| S:3627 E:3631 ||| CC
LDL  ||| S:3631 E:3635 ||| NNP
cholesterol  ||| S:3635 E:3647 ||| NN
and  ||| S:3647 E:3659 ||| CC
triglyceride  ||| S:3659 E:3672 ||| JJ
levels  ||| S:3672 E:3679 ||| NNS
but  ||| S:3679 E:3683 ||| CC
did  ||| S:3683 E:3687 ||| VBD
not  ||| S:3687 E:3691 ||| RB
significantly  ||| S:3691 E:3705 ||| RB
change  ||| S:3705 E:3712 ||| VB
high  ||| S:3712 E:3725 ||| JJ
density  ||| S:3725 E:3733 ||| NN
lipoprotein  ||| S:3733 E:3745 ||| NNS
( ||| S:3745 E:3746 ||| -LRB-
HDL ||| S:3746 E:3749 ||| NNP
)  ||| S:3749 E:3751 ||| -RRB-
cholesterol  ||| S:3751 E:3763 ||| NN
by  ||| S:3763 E:3766 ||| IN
16  ||| S:3766 E:3769 ||| CD
weeks ||| S:3769 E:3774 ||| NNS
.  ||| S:3774 E:3776 ||| .
By  ||| S:3776 E:3779 ||| IN
16  ||| S:3779 E:3790 ||| CD
weeks ||| S:3790 E:3795 ||| NNS
,  ||| S:3795 E:3797 ||| ,
the  ||| S:3797 E:3801 ||| DT
adjusted  ||| S:3801 E:3810 ||| JJ
mean  ||| S:3810 E:3815 ||| JJ
LDL  ||| S:3815 E:3819 ||| NNP
cholesterol  ||| S:3819 E:3831 ||| NN
decreased  ||| S:3831 E:3841 ||| VBD
to  ||| S:3841 E:3844 ||| TO
72  ||| S:3844 E:3855 ||| CD
mg ||| S:3855 E:3857 ||| CD
/ ||| S:3857 E:3858 ||| CD
dL  ||| S:3858 E:3861 ||| NN
in  ||| S:3861 E:3864 ||| IN
atorvastatin-treated  ||| S:3864 E:3885 ||| JJ
patients  ||| S:3885 E:3894 ||| NNS
but  ||| S:3894 E:3898 ||| CC
increased  ||| S:3898 E:3908 ||| VBN
to  ||| S:3908 E:3911 ||| TO
135  ||| S:3911 E:3923 ||| CD
mg ||| S:3923 E:3925 ||| CD
/ ||| S:3925 E:3926 ||| CD
dL  ||| S:3926 E:3929 ||| NN
among  ||| S:3929 E:3935 ||| IN
placebo-treated  ||| S:3935 E:3951 ||| JJ
patients ||| S:3951 E:3959 ||| NNS
.  ||| S:3959 E:3961 ||| .
No  ||| S:3961 E:3964 ||| DT
serious  ||| S:3964 E:3972 ||| JJ
adverse  ||| S:3972 E:3988 ||| JJ
events  ||| S:3988 E:3995 ||| NNS
occurred  ||| S:3995 E:4004 ||| VBD
as  ||| S:4004 E:4007 ||| IN
the  ||| S:4007 E:4011 ||| DT
result  ||| S:4011 E:4018 ||| NN
of  ||| S:4018 E:4021 ||| IN
treatment  ||| S:4021 E:4031 ||| NN
with  ||| S:4031 E:4044 ||| IN
atorvastatin ||| S:4044 E:4056 ||| NN
,  ||| S:4056 E:4058 ||| ,
although  ||| S:4058 E:4067 ||| IN
reversible  ||| S:4067 E:4078 ||| JJ
liver  ||| S:4078 E:4084 ||| NN
transaminase  ||| S:4084 E:4105 ||| NNS
elevation  ||| S:4105 E:4115 ||| VBP
more  ||| S:4115 E:4120 ||| JJR
than  ||| S:4120 E:4125 ||| IN
three  ||| S:4125 E:4131 ||| CD
times  ||| S:4131 E:4137 ||| NNS
the  ||| S:4137 E:4141 ||| DT
upper  ||| S:4141 E:4147 ||| JJ
limit  ||| S:4147 E:4153 ||| NN
of  ||| S:4153 E:4156 ||| IN
normal  ||| S:4156 E:4171 ||| JJ
occurred  ||| S:4171 E:4180 ||| NN
in  ||| S:4180 E:4183 ||| IN
2.5 ||| S:4183 E:4186 ||| CD
%  ||| S:4186 E:4188 ||| NN
of  ||| S:4188 E:4191 ||| IN
atorvastatin-treated  ||| S:4191 E:4212 ||| JJ
versus  ||| S:4212 E:4219 ||| IN
0.6 ||| S:4219 E:4222 ||| CD
%  ||| S:4222 E:4224 ||| NN
of  ||| S:4224 E:4235 ||| IN
placebo-treated  ||| S:4235 E:4251 ||| JJ
patients  ||| S:4251 E:4260 ||| NNS
( ||| S:4260 E:4261 ||| -LRB-
p  ||| S:4261 E:4263 ||| FW
< ||| S:4263 E:4265 ||| SYM
0.001 ||| S:4265 E:4270 ||| FW
) ||| S:4270 E:4271 ||| -RRB-
.  ||| S:4271 E:4295 ||| .
The  ||| S:4295 E:4299 ||| DT
MIRACuLous  ||| S:4299 E:4318 ||| JJ
The  ||| S:4318 E:4322 ||| DT
efficacy  ||| S:4322 E:4331 ||| NN
and  ||| S:4331 E:4335 ||| CC
safety  ||| S:4335 E:4342 ||| NN
findings  ||| S:4342 E:4351 ||| NNS
from  ||| S:4351 E:4356 ||| IN
MIRACL  ||| S:4356 E:4363 ||| NNP
were  ||| S:4363 E:4368 ||| VBD
unique  ||| S:4368 E:4383 ||| JJ
for  ||| S:4383 E:4387 ||| IN
a  ||| S:4387 E:4389 ||| DT
number  ||| S:4389 E:4396 ||| NN
of  ||| S:4396 E:4399 ||| IN
reasons ||| S:4399 E:4406 ||| NNS
.  ||| S:4406 E:4408 ||| .
Although  ||| S:4408 E:4417 ||| IN
lipid-lowering  ||| S:4417 E:4432 ||| JJ
therapy  ||| S:4432 E:4448 ||| NN
was  ||| S:4448 E:4452 ||| VBD
associated  ||| S:4452 E:4463 ||| VBN
with  ||| S:4463 E:4468 ||| IN
a  ||| S:4468 E:4470 ||| DT
significantly  ||| S:4470 E:4484 ||| RB
lower  ||| S:4484 E:4490 ||| JJR
mortality  ||| S:4490 E:4500 ||| NN
when  ||| S:4500 E:4513 ||| WRB
initiated  ||| S:4513 E:4523 ||| VBN
early  ||| S:4523 E:4529 ||| RB
after  ||| S:4529 E:4535 ||| IN
an  ||| S:4535 E:4538 ||| DT
acute  ||| S:4538 E:4544 ||| JJ
coronary  ||| S:4544 E:4553 ||| JJ
syndrome  ||| S:4553 E:4562 ||| NN
in  ||| S:4562 E:4565 ||| IN
two  ||| S:4565 E:4577 ||| CD
large  ||| S:4577 E:4583 ||| JJ
observational  ||| S:4583 E:4597 ||| JJ
studies  ||| S:4597 E:4605 ||| NNS
[  ||| S:4605 E:4607 ||| -LRB-
6  ||| S:4607 E:4609 ||| CD
7  ||| S:4609 E:4611 ||| CD
]  ||| S:4611 E:4613 ||| -RRB-
,  ||| S:4613 E:4615 ||| ,
MIRACL  ||| S:4615 E:4622 ||| NNP
was  ||| S:4622 E:4626 ||| VBD
the  ||| S:4626 E:4630 ||| DT
first  ||| S:4630 E:4644 ||| JJ
randomized  ||| S:4644 E:4655 ||| JJ
trial  ||| S:4655 E:4661 ||| NN
to  ||| S:4661 E:4664 ||| TO
suggest  ||| S:4664 E:4672 ||| VB
that  ||| S:4672 E:4677 ||| IN
statins  ||| S:4677 E:4685 ||| NNS
confer  ||| S:4685 E:4692 ||| VBP
clinical  ||| S:4692 E:4709 ||| JJ
benefits  ||| S:4709 E:4718 ||| NNS
in  ||| S:4718 E:4721 ||| IN
this  ||| S:4721 E:4726 ||| DT
setting ||| S:4726 E:4733 ||| NN
.  ||| S:4733 E:4735 ||| .
It  ||| S:4735 E:4738 ||| PRP
was  ||| S:4738 E:4742 ||| VBD
also  ||| S:4742 E:4747 ||| RB
the  ||| S:4747 E:4751 ||| DT
first  ||| S:4751 E:4757 ||| JJ
trial  ||| S:4757 E:4763 ||| NN
to  ||| S:4763 E:4774 ||| TO
identify  ||| S:4774 E:4783 ||| VB
a  ||| S:4783 E:4785 ||| DT
short-term  ||| S:4785 E:4796 ||| JJ
( ||| S:4796 E:4797 ||| -LRB-
ie ||| S:4797 E:4799 ||| UH
,  ||| S:4799 E:4801 ||| ,
within  ||| S:4801 E:4808 ||| IN
16  ||| S:4808 E:4811 ||| CD
weeks ||| S:4811 E:4816 ||| NNS
)  ||| S:4816 E:4818 ||| -RRB-
clinical  ||| S:4818 E:4835 ||| JJ
benefit  ||| S:4835 E:4843 ||| NN
from  ||| S:4843 E:4848 ||| IN
statin  ||| S:4848 E:4855 ||| JJ
therapy ||| S:4855 E:4862 ||| NN
;  ||| S:4862 E:4864 ||| :
in  ||| S:4864 E:4867 ||| IN
previous  ||| S:4867 E:4876 ||| JJ
secondary  ||| S:4876 E:4894 ||| JJ
prevention  ||| S:4894 E:4905 ||| NN
trials ||| S:4905 E:4911 ||| NNS
,  ||| S:4911 E:4913 ||| ,
the  ||| S:4913 E:4917 ||| DT
benefit  ||| S:4917 E:4925 ||| NN
of  ||| S:4925 E:4928 ||| IN
statin  ||| S:4928 E:4935 ||| JJ
therapy  ||| S:4935 E:4943 ||| NN
was  ||| S:4943 E:4947 ||| VBD
not  ||| S:4947 E:4959 ||| RB
evident  ||| S:4959 E:4967 ||| JJ
for  ||| S:4967 E:4971 ||| IN
one  ||| S:4971 E:4975 ||| CD
to  ||| S:4975 E:4978 ||| TO
two  ||| S:4978 E:4982 ||| CD
years ||| S:4982 E:4987 ||| NNS
.  ||| S:4987 E:4989 ||| .
And ||| S:4989 E:4992 ||| CC
,  ||| S:4992 E:4994 ||| ,
while  ||| S:4994 E:5000 ||| IN
clinical  ||| S:5000 E:5009 ||| JJ
trial  ||| S:5009 E:5023 ||| NN
safety  ||| S:5023 E:5030 ||| NN
endpoints  ||| S:5030 E:5040 ||| NNS
may  ||| S:5040 E:5044 ||| MD
be  ||| S:5044 E:5047 ||| VB
considered  ||| S:5047 E:5058 ||| VBN
less  ||| S:5058 E:5063 ||| RBR
glamorous ||| S:5063 E:5072 ||| JJ
,  ||| S:5072 E:5074 ||| ,
MIRACL ||| S:5074 E:5080 ||| NNP
's  ||| S:5080 E:5091 ||| POS
most  ||| S:5091 E:5096 ||| RBS
important  ||| S:5096 E:5106 ||| JJ
contribution  ||| S:5106 E:5119 ||| NN
may  ||| S:5119 E:5123 ||| MD
have  ||| S:5123 E:5128 ||| VB
been  ||| S:5128 E:5133 ||| VBN
that  ||| S:5133 E:5138 ||| IN
high-dose  ||| S:5138 E:5156 ||| JJ
statin  ||| S:5156 E:5163 ||| JJ
therapy  ||| S:5163 E:5171 ||| NN
was  ||| S:5171 E:5175 ||| VBD
not  ||| S:5175 E:5179 ||| RB
associated  ||| S:5179 E:5190 ||| VBN
with  ||| S:5190 E:5195 ||| IN
serious  ||| S:5195 E:5203 ||| JJ
harm ||| S:5203 E:5207 ||| NN
,  ||| S:5207 E:5217 ||| ,
despite  ||| S:5217 E:5225 ||| IN
its  ||| S:5225 E:5229 ||| PRP$
use  ||| S:5229 E:5233 ||| NN
in  ||| S:5233 E:5236 ||| IN
the  ||| S:5236 E:5240 ||| DT
unstable  ||| S:5240 E:5249 ||| JJ
setting ||| S:5249 E:5256 ||| NN
.  ||| S:5256 E:5258 ||| .
Earlier  ||| S:5258 E:5266 ||| RBR
secondary  ||| S:5266 E:5284 ||| JJ
prevention  ||| S:5284 E:5295 ||| NN
statin  ||| S:5295 E:5302 ||| NN
trials  ||| S:5302 E:5309 ||| NNS
had  ||| S:5309 E:5313 ||| VBD
excluded  ||| S:5313 E:5322 ||| VBN
patients  ||| S:5322 E:5331 ||| NNS
with  ||| S:5331 E:5344 ||| IN
unstable  ||| S:5344 E:5353 ||| JJ
coronary  ||| S:5353 E:5362 ||| NNS
syndromes  ||| S:5362 E:5372 ||| VBP
largely  ||| S:5372 E:5380 ||| RB
out  ||| S:5380 E:5384 ||| RB
of  ||| S:5384 E:5387 ||| IN
theoretical  ||| S:5387 E:5407 ||| JJ
concern  ||| S:5407 E:5415 ||| NN
that  ||| S:5415 E:5420 ||| IN
statin-mediated  ||| S:5420 E:5436 ||| JJ
reductions  ||| S:5436 E:5447 ||| NNS
in  ||| S:5447 E:5450 ||| IN
vascular  ||| S:5450 E:5459 ||| JJ
smooth  ||| S:5459 E:5474 ||| JJ
muscle  ||| S:5474 E:5481 ||| NN
cell  ||| S:5481 E:5486 ||| NN
proliferation  ||| S:5486 E:5500 ||| NN
might  ||| S:5500 E:5506 ||| MD
destabilize  ||| S:5506 E:5518 ||| VB
healing  ||| S:5518 E:5526 ||| JJ
plaque ||| S:5526 E:5532 ||| NN
.  ||| S:5532 E:5542 ||| .
That  ||| S:5542 E:5547 ||| IN
no  ||| S:5547 E:5550 ||| DT
harm  ||| S:5550 E:5555 ||| NN
resulted  ||| S:5555 E:5564 ||| VBD
from  ||| S:5564 E:5569 ||| IN
this  ||| S:5569 E:5574 ||| DT
aggressive  ||| S:5574 E:5585 ||| JJ
treatment  ||| S:5585 E:5603 ||| NN
strategy  ||| S:5603 E:5612 ||| NN
should  ||| S:5612 E:5619 ||| MD
allay  ||| S:5619 E:5625 ||| VB
theoretical  ||| S:5625 E:5637 ||| JJ
fears  ||| S:5637 E:5643 ||| NNS
and  ||| S:5643 E:5647 ||| CC
by  ||| S:5647 E:5650 ||| IN
doing  ||| S:5650 E:5656 ||| VBG
so  ||| S:5656 E:5667 ||| RB
remove  ||| S:5667 E:5674 ||| VB
a  ||| S:5674 E:5676 ||| DT
major  ||| S:5676 E:5682 ||| JJ
obstacle  ||| S:5682 E:5691 ||| NN
to  ||| S:5691 E:5694 ||| TO
the  ||| S:5694 E:5698 ||| DT
inpatient  ||| S:5698 E:5708 ||| JJ
initiation  ||| S:5708 E:5719 ||| NN
of  ||| S:5719 E:5730 ||| IN
lipid-lowing  ||| S:5730 E:5743 ||| JJ
therapy  ||| S:5743 E:5751 ||| NN
after  ||| S:5751 E:5757 ||| IN
coronary  ||| S:5757 E:5766 ||| JJ
events ||| S:5766 E:5772 ||| NNS
.  ||| S:5772 E:5796 ||| .
The  ||| S:5796 E:5800 ||| DT
not  ||| S:5800 E:5804 ||| RB
so  ||| S:5804 E:5807 ||| RB
MIRACuLous  ||| S:5807 E:5826 ||| JJ
Despite  ||| S:5826 E:5834 ||| IN
these  ||| S:5834 E:5840 ||| DT
unique  ||| S:5840 E:5847 ||| JJ
and  ||| S:5847 E:5851 ||| CC
important  ||| S:5851 E:5861 ||| JJ
findings ||| S:5861 E:5869 ||| NNS
,  ||| S:5869 E:5871 ||| ,
there  ||| S:5871 E:5877 ||| EX
were  ||| S:5877 E:5890 ||| VBD
a  ||| S:5890 E:5892 ||| DT
number  ||| S:5892 E:5899 ||| NN
of  ||| S:5899 E:5902 ||| IN
inherent  ||| S:5902 E:5911 ||| JJ
study  ||| S:5911 E:5917 ||| NN
limitations  ||| S:5917 E:5929 ||| NNS
worth  ||| S:5929 E:5935 ||| IN
noting ||| S:5935 E:5941 ||| VBG
.  ||| S:5941 E:5943 ||| .
First  ||| S:5943 E:5957 ||| NNP
and  ||| S:5957 E:5961 ||| CC
foremost ||| S:5961 E:5969 ||| RB
,  ||| S:5969 E:5971 ||| ,
the  ||| S:5971 E:5975 ||| DT
possibility  ||| S:5975 E:5987 ||| NN
of  ||| S:5987 E:5990 ||| IN
a  ||| S:5990 E:5992 ||| DT
null  ||| S:5992 E:5997 ||| JJ
treatment  ||| S:5997 E:6007 ||| NN
effect  ||| S:6007 E:6022 ||| NN
cannot  ||| S:6022 E:6029 ||| RB
be  ||| S:6029 E:6032 ||| VB
ignored  ||| S:6032 E:6040 ||| VBN
given  ||| S:6040 E:6046 ||| VBN
the  ||| S:6046 E:6050 ||| DT
wide  ||| S:6050 E:6055 ||| JJ
confidence  ||| S:6055 E:6066 ||| NN
intervals  ||| S:6066 E:6076 ||| NNS
( ||| S:6076 E:6077 ||| -LRB-
and  ||| S:6077 E:6089 ||| CC
hence  ||| S:6089 E:6095 ||| RB
marginally  ||| S:6095 E:6106 ||| RB
significant  ||| S:6106 E:6118 ||| JJ
p  ||| S:6118 E:6120 ||| JJ
value  ||| S:6120 E:6126 ||| NN
of  ||| S:6126 E:6129 ||| IN
0.048 ||| S:6129 E:6134 ||| CD
)  ||| S:6134 E:6136 ||| -RRB-
for  ||| S:6136 E:6140 ||| IN
the  ||| S:6140 E:6152 ||| DT
effect  ||| S:6152 E:6159 ||| NN
of  ||| S:6159 E:6162 ||| IN
atorvastatin  ||| S:6162 E:6175 ||| NN
on  ||| S:6175 E:6178 ||| IN
the  ||| S:6178 E:6182 ||| DT
primary  ||| S:6182 E:6190 ||| JJ
efficacy  ||| S:6190 E:6199 ||| JJ
endpoint ||| S:6199 E:6207 ||| NN
.  ||| S:6207 E:6217 ||| .
Furthermore ||| S:6217 E:6228 ||| RB
,  ||| S:6228 E:6230 ||| ,
while  ||| S:6230 E:6236 ||| IN
the  ||| S:6236 E:6240 ||| DT
number  ||| S:6240 E:6247 ||| NN
of  ||| S:6247 E:6250 ||| IN
patients  ||| S:6250 E:6259 ||| NNS
lost  ||| S:6259 E:6264 ||| VBD
to  ||| S:6264 E:6267 ||| TO
follow  ||| S:6267 E:6274 ||| VB
up  ||| S:6274 E:6285 ||| RB
was  ||| S:6285 E:6289 ||| VBD
small ||| S:6289 E:6294 ||| JJ
,  ||| S:6294 E:6296 ||| ,
if  ||| S:6296 E:6299 ||| IN
adverse  ||| S:6299 E:6307 ||| JJ
events  ||| S:6307 E:6314 ||| NNS
had  ||| S:6314 E:6318 ||| VBD
occurred  ||| S:6318 E:6327 ||| VBN
in  ||| S:6327 E:6330 ||| IN
those  ||| S:6330 E:6336 ||| DT
treated  ||| S:6336 E:6352 ||| VBN
with  ||| S:6352 E:6357 ||| IN
atorvastatin  ||| S:6357 E:6370 ||| NNS
( ||| S:6370 E:6371 ||| -LRB-
n  ||| S:6371 E:6373 ||| CD
=  ||| S:6373 E:6375 ||| SYM
3 ||| S:6375 E:6376 ||| LS
)  ||| S:6376 E:6378 ||| -RRB-
but  ||| S:6378 E:6382 ||| CC
not  ||| S:6382 E:6386 ||| RB
placebo  ||| S:6386 E:6394 ||| JJ
( ||| S:6394 E:6395 ||| -LRB-
n  ||| S:6395 E:6397 ||| CD
=  ||| S:6397 E:6399 ||| SYM
8 ||| S:6399 E:6400 ||| CD
) ||| S:6400 E:6401 ||| -RRB-
,  ||| S:6401 E:6403 ||| ,
the  ||| S:6403 E:6415 ||| DT
overall  ||| S:6415 E:6423 ||| JJ
trial  ||| S:6423 E:6429 ||| NN
results  ||| S:6429 E:6437 ||| NNS
may  ||| S:6437 E:6441 ||| MD
have  ||| S:6441 E:6446 ||| VB
been  ||| S:6446 E:6451 ||| VBN
neutral  ||| S:6451 E:6459 ||| JJ
rather  ||| S:6459 E:6466 ||| RB
than  ||| S:6466 E:6479 ||| IN
positive ||| S:6479 E:6487 ||| JJ
.  ||| S:6487 E:6497 ||| .
The  ||| S:6497 E:6501 ||| DT
types  ||| S:6501 E:6507 ||| NNS
of  ||| S:6507 E:6510 ||| IN
events  ||| S:6510 E:6517 ||| NNS
prevented  ||| S:6517 E:6527 ||| VBN
in  ||| S:6527 E:6530 ||| IN
MIRACL  ||| S:6530 E:6537 ||| NNP
are  ||| S:6537 E:6541 ||| VBP
also  ||| S:6541 E:6546 ||| RB
worth  ||| S:6546 E:6560 ||| JJ
noting ||| S:6560 E:6566 ||| NN
.  ||| S:6566 E:6568 ||| .
While  ||| S:6568 E:6574 ||| IN
rehospitalization  ||| S:6574 E:6592 ||| NN
for  ||| S:6592 E:6596 ||| IN
recurrent  ||| S:6596 E:6606 ||| JJ
myocardial  ||| S:6606 E:6625 ||| JJ
ischemia  ||| S:6625 E:6634 ||| NN
is  ||| S:6634 E:6637 ||| VBZ
an  ||| S:6637 E:6640 ||| DT
important  ||| S:6640 E:6650 ||| JJ
determinant  ||| S:6650 E:6662 ||| NN
of  ||| S:6662 E:6665 ||| IN
quality  ||| S:6665 E:6673 ||| NN
of  ||| S:6673 E:6676 ||| IN
life  ||| S:6676 E:6681 ||| NN
and  ||| S:6681 E:6693 ||| CC
health  ||| S:6693 E:6700 ||| NN
care  ||| S:6700 E:6705 ||| NN
costs ||| S:6705 E:6710 ||| NNS
,  ||| S:6710 E:6712 ||| ,
other  ||| S:6712 E:6718 ||| JJ
important  ||| S:6718 E:6728 ||| JJ
endpoints  ||| S:6728 E:6738 ||| NN
were  ||| S:6738 E:6743 ||| VBD
not  ||| S:6743 E:6755 ||| RB
significantly  ||| S:6755 E:6769 ||| RB
affected  ||| S:6769 E:6778 ||| VBN
( ||| S:6778 E:6779 ||| -LRB-
eg ||| S:6779 E:6781 ||| UH
,  ||| S:6781 E:6783 ||| ,
death ||| S:6783 E:6788 ||| NN
,  ||| S:6788 E:6790 ||| ,
myocardial  ||| S:6790 E:6801 ||| JJ
infarction ||| S:6801 E:6811 ||| NN
,  ||| S:6811 E:6821 ||| ,
resuscitated  ||| S:6821 E:6834 ||| JJ
sudden  ||| S:6834 E:6841 ||| JJ
cardiac  ||| S:6841 E:6849 ||| JJ
death ||| S:6849 E:6854 ||| NN
,  ||| S:6854 E:6856 ||| ,
worsening  ||| S:6856 E:6866 ||| VBG
heart  ||| S:6866 E:6872 ||| NN
failure ||| S:6872 E:6879 ||| NN
,  ||| S:6879 E:6889 ||| ,
need  ||| S:6889 E:6894 ||| VBP
for  ||| S:6894 E:6898 ||| IN
coronary  ||| S:6898 E:6907 ||| JJ
revascularization ||| S:6907 E:6924 ||| NN
,  ||| S:6924 E:6926 ||| ,
etc ||| S:6926 E:6929 ||| FW
) ||| S:6929 E:6930 ||| -RRB-
.  ||| S:6930 E:6932 ||| .
The  ||| S:6932 E:6936 ||| DT
question  ||| S:6936 E:6945 ||| NN
of  ||| S:6945 E:6956 ||| IN
whether  ||| S:6956 E:6964 ||| IN
statins  ||| S:6964 E:6972 ||| NNS
can  ||| S:6972 E:6976 ||| MD
prevent  ||| S:6976 E:6984 ||| VB
these  ||| S:6984 E:6990 ||| DT
and  ||| S:6990 E:6994 ||| CC
other  ||| S:6994 E:7000 ||| JJ
adverse  ||| S:7000 E:7008 ||| JJ
events  ||| S:7008 E:7023 ||| NNS
when  ||| S:7023 E:7028 ||| WRB
initiated  ||| S:7028 E:7038 ||| VBN
soon  ||| S:7038 E:7043 ||| RB
after  ||| S:7043 E:7049 ||| IN
an  ||| S:7049 E:7052 ||| DT
acute  ||| S:7052 E:7058 ||| JJ
coronary  ||| S:7058 E:7067 ||| JJ
syndrome  ||| S:7067 E:7076 ||| NN
will  ||| S:7076 E:7089 ||| MD
require  ||| S:7089 E:7097 ||| VB
further  ||| S:7097 E:7105 ||| JJ
study ||| S:7105 E:7110 ||| NN
.  ||| S:7110 E:7120 ||| .
The  ||| S:7120 E:7124 ||| DT
short  ||| S:7124 E:7130 ||| JJ
duration  ||| S:7130 E:7139 ||| NN
of  ||| S:7139 E:7142 ||| IN
follow-up  ||| S:7142 E:7152 ||| NNP
is  ||| S:7152 E:7155 ||| VBZ
also  ||| S:7155 E:7160 ||| RB
particularly  ||| S:7160 E:7181 ||| RB
troubling ||| S:7181 E:7190 ||| JJ
.  ||| S:7190 E:7192 ||| .
While  ||| S:7192 E:7198 ||| IN
it  ||| S:7198 E:7201 ||| PRP
is  ||| S:7201 E:7204 ||| VBZ
impressive  ||| S:7204 E:7215 ||| JJ
that  ||| S:7215 E:7220 ||| IN
a  ||| S:7220 E:7222 ||| DT
clinical  ||| S:7222 E:7231 ||| JJ
benefit  ||| S:7231 E:7247 ||| NN
was  ||| S:7247 E:7251 ||| VBD
realized  ||| S:7251 E:7260 ||| VBN
after  ||| S:7260 E:7266 ||| IN
only  ||| S:7266 E:7271 ||| RB
16  ||| S:7271 E:7274 ||| CD
weeks  ||| S:7274 E:7280 ||| NNS
of  ||| S:7280 E:7283 ||| IN
statin  ||| S:7283 E:7290 ||| JJ
therapy ||| S:7290 E:7297 ||| NN
,  ||| S:7297 E:7299 ||| ,
the  ||| S:7299 E:7311 ||| DT
increased  ||| S:7311 E:7321 ||| JJ
risk  ||| S:7321 E:7326 ||| NN
of  ||| S:7326 E:7329 ||| IN
adverse  ||| S:7329 E:7337 ||| JJ
clinical  ||| S:7337 E:7346 ||| JJ
events  ||| S:7346 E:7353 ||| NNS
persists  ||| S:7353 E:7370 ||| VBZ
throughout  ||| S:7370 E:7381 ||| IN
the  ||| S:7381 E:7385 ||| DT
year  ||| S:7385 E:7390 ||| NN
following  ||| S:7390 E:7400 ||| VBG
an  ||| S:7400 E:7403 ||| DT
acute  ||| S:7403 E:7409 ||| JJ
coronary  ||| S:7409 E:7418 ||| JJ
syndrome ||| S:7418 E:7426 ||| NN
.  ||| S:7426 E:7436 ||| .
Without  ||| S:7436 E:7444 ||| IN
longer  ||| S:7444 E:7451 ||| JJR
clinical  ||| S:7451 E:7460 ||| NNS
follow  ||| S:7460 E:7467 ||| VBP
up ||| S:7467 E:7469 ||| RB
,  ||| S:7469 E:7471 ||| ,
it  ||| S:7471 E:7474 ||| PRP
is  ||| S:7474 E:7477 ||| VBZ
not  ||| S:7477 E:7481 ||| RB
possible  ||| S:7481 E:7490 ||| JJ
to  ||| S:7490 E:7501 ||| TO
assess  ||| S:7501 E:7508 ||| VB
the  ||| S:7508 E:7512 ||| DT
intermediate-term  ||| S:7512 E:7530 ||| JJ
effect  ||| S:7530 E:7537 ||| NN
( ||| S:7537 E:7538 ||| -LRB-
if  ||| S:7538 E:7541 ||| IN
any ||| S:7541 E:7544 ||| DT
)  ||| S:7544 E:7546 ||| -RRB-
of  ||| S:7546 E:7557 ||| IN
atorvastatin  ||| S:7557 E:7570 ||| NN
on  ||| S:7570 E:7573 ||| IN
hard  ||| S:7573 E:7578 ||| JJ
endpoints  ||| S:7578 E:7588 ||| JJ
such  ||| S:7588 E:7593 ||| JJ
as  ||| S:7593 E:7596 ||| IN
death  ||| S:7596 E:7602 ||| NN
or  ||| S:7602 E:7605 ||| CC
myocardial  ||| S:7605 E:7624 ||| JJ
infarction ||| S:7624 E:7634 ||| NN
.  ||| S:7634 E:7636 ||| .
To  ||| S:7636 E:7639 ||| TO
do  ||| S:7639 E:7642 ||| VB
so  ||| S:7642 E:7645 ||| RB
would  ||| S:7645 E:7651 ||| MD
be  ||| S:7651 E:7654 ||| VB
critical  ||| S:7654 E:7663 ||| JJ
in  ||| S:7663 E:7666 ||| IN
light  ||| S:7666 E:7672 ||| NN
of  ||| S:7672 E:7675 ||| IN
the  ||| S:7675 E:7679 ||| DT
lack  ||| S:7679 E:7692 ||| NN
of  ||| S:7692 E:7695 ||| IN
effect  ||| S:7695 E:7702 ||| NN
on  ||| S:7702 E:7705 ||| IN
these  ||| S:7705 E:7711 ||| DT
important  ||| S:7711 E:7721 ||| JJ
endpoints  ||| S:7721 E:7731 ||| NN
at  ||| S:7731 E:7734 ||| IN
16  ||| S:7734 E:7737 ||| CD
weeks ||| S:7737 E:7742 ||| NNS
.  ||| S:7742 E:7752 ||| .
Unfortunately ||| S:7752 E:7765 ||| RB
,  ||| S:7765 E:7767 ||| ,
no  ||| S:7767 E:7770 ||| DT
late  ||| S:7770 E:7775 ||| JJ
clinical  ||| S:7775 E:7784 ||| NNS
follow  ||| S:7784 E:7791 ||| VBP
up  ||| S:7791 E:7794 ||| RB
is  ||| S:7794 E:7797 ||| VBZ
planned ||| S:7797 E:7804 ||| VBN
.  ||| S:7804 E:7814 ||| .
There  ||| S:7814 E:7820 ||| EX
were  ||| S:7820 E:7825 ||| VBD
also  ||| S:7825 E:7830 ||| RB
a  ||| S:7830 E:7832 ||| DT
number  ||| S:7832 E:7839 ||| NN
of  ||| S:7839 E:7842 ||| IN
limitations  ||| S:7842 E:7854 ||| NNS
that  ||| S:7854 E:7859 ||| WDT
may  ||| S:7859 E:7863 ||| MD
have  ||| S:7863 E:7876 ||| VB
hampered  ||| S:7876 E:7885 ||| VBN
the  ||| S:7885 E:7889 ||| DT
study ||| S:7889 E:7894 ||| NN
's  ||| S:7894 E:7897 ||| POS
generalizability ||| S:7897 E:7913 ||| NN
.  ||| S:7913 E:7915 ||| .
First ||| S:7915 E:7920 ||| NNP
,  ||| S:7920 E:7922 ||| ,
patients  ||| S:7922 E:7931 ||| NNS
who  ||| S:7931 E:7943 ||| WP
underwent  ||| S:7943 E:7953 ||| VBD
recent  ||| S:7953 E:7960 ||| JJ
revascularization  ||| S:7960 E:7978 ||| NN
or  ||| S:7978 E:7981 ||| CC
in  ||| S:7981 E:7984 ||| IN
whom  ||| S:7984 E:7989 ||| WP
it  ||| S:7989 E:7992 ||| PRP
was  ||| S:7992 E:8004 ||| VBD
planned  ||| S:8004 E:8012 ||| VBN
were  ||| S:8012 E:8017 ||| VBD
excluded ||| S:8017 E:8025 ||| VBN
.  ||| S:8025 E:8027 ||| .
Specifically ||| S:8027 E:8039 ||| RB
,  ||| S:8039 E:8041 ||| ,
patients  ||| S:8041 E:8050 ||| NNS
who  ||| S:8050 E:8054 ||| WP
underwent  ||| S:8054 E:8072 ||| VBD
percutaneous  ||| S:8072 E:8085 ||| FW
transluminal  ||| S:8085 E:8098 ||| FW
coronary  ||| S:8098 E:8107 ||| FW
angioplasty  ||| S:8107 E:8119 ||| FW
( ||| S:8119 E:8120 ||| -LRB-
PTCA ||| S:8120 E:8124 ||| NNP
)  ||| S:8124 E:8126 ||| -RRB-
or  ||| S:8126 E:8137 ||| CC
coronary  ||| S:8137 E:8146 ||| FW
artery  ||| S:8146 E:8153 ||| FW
bypass  ||| S:8153 E:8160 ||| FW
graft  ||| S:8160 E:8166 ||| FW
( ||| S:8166 E:8167 ||| -LRB-
CABG ||| S:8167 E:8171 ||| NNP
)  ||| S:8171 E:8173 ||| -RRB-
surgery  ||| S:8173 E:8181 ||| NN
within  ||| S:8181 E:8188 ||| IN
the  ||| S:8188 E:8200 ||| DT
previous  ||| S:8200 E:8209 ||| JJ
three  ||| S:8209 E:8215 ||| CD
or  ||| S:8215 E:8218 ||| CC
six  ||| S:8218 E:8222 ||| CD
months  ||| S:8222 E:8229 ||| NNS
respectively  ||| S:8229 E:8242 ||| RB
were  ||| S:8242 E:8247 ||| VBD
not  ||| S:8247 E:8251 ||| RB
eligible  ||| S:8251 E:8268 ||| JJ
for  ||| S:8268 E:8272 ||| IN
inclusion ||| S:8272 E:8281 ||| NN
.  ||| S:8281 E:8283 ||| .
The  ||| S:8283 E:8287 ||| DT
investigators  ||| S:8287 E:8301 ||| NNS
reasoned  ||| S:8301 E:8310 ||| VBD
that  ||| S:8310 E:8315 ||| DT
recurrent  ||| S:8315 E:8333 ||| JJ
ischemic  ||| S:8333 E:8342 ||| JJ
events  ||| S:8342 E:8349 ||| NNS
in  ||| S:8349 E:8352 ||| IN
this  ||| S:8352 E:8357 ||| DT
population  ||| S:8357 E:8368 ||| NN
were  ||| S:8368 E:8373 ||| VBD
likely  ||| S:8373 E:8380 ||| JJ
to  ||| S:8380 E:8383 ||| TO
result  ||| S:8383 E:8398 ||| VB
from  ||| S:8398 E:8403 ||| IN
restenosis  ||| S:8403 E:8414 ||| NN
or  ||| S:8414 E:8417 ||| CC
bypass  ||| S:8417 E:8424 ||| VB
graft  ||| S:8424 E:8430 ||| JJ
closure  ||| S:8430 E:8438 ||| NN
and  ||| S:8438 E:8442 ||| CC
that  ||| S:8442 E:8447 ||| DT
statins  ||| S:8447 E:8463 ||| NN
would  ||| S:8463 E:8469 ||| MD
be  ||| S:8469 E:8472 ||| VB
less  ||| S:8472 E:8477 ||| RBR
likely  ||| S:8477 E:8484 ||| JJ
to  ||| S:8484 E:8487 ||| TO
affect  ||| S:8487 E:8494 ||| VB
these  ||| S:8494 E:8500 ||| DT
processes  ||| S:8500 E:8510 ||| NNS
[  ||| S:8510 E:8512 ||| -LRB-
8  ||| S:8512 E:8514 ||| CD
]  ||| S:8514 E:8516 ||| -RRB-
.  ||| S:8516 E:8526 ||| .
Nevertheless ||| S:8526 E:8538 ||| RB
,  ||| S:8538 E:8540 ||| ,
a  ||| S:8540 E:8542 ||| DT
number  ||| S:8542 E:8549 ||| NN
of  ||| S:8549 E:8552 ||| IN
trials  ||| S:8552 E:8559 ||| NNS
have  ||| S:8559 E:8564 ||| VBP
established  ||| S:8564 E:8576 ||| VBN
the  ||| S:8576 E:8588 ||| DT
benefits  ||| S:8588 E:8597 ||| NNS
of  ||| S:8597 E:8600 ||| IN
statin  ||| S:8600 E:8607 ||| JJ
therapy  ||| S:8607 E:8624 ||| NN
early  ||| S:8624 E:8630 ||| RB
after  ||| S:8630 E:8636 ||| IN
coronary  ||| S:8636 E:8653 ||| JJ
revascularization  ||| S:8653 E:8671 ||| NNS
[  ||| S:8671 E:8673 ||| -LRB-
9  ||| S:8673 E:8675 ||| CD
10  ||| S:8675 E:8678 ||| CD
11  ||| S:8678 E:8681 ||| CD
]  ||| S:8681 E:8683 ||| -RRB-
.  ||| S:8683 E:8685 ||| .
Furthermore ||| S:8685 E:8696 ||| RB
,  ||| S:8696 E:8698 ||| ,
a  ||| S:8698 E:8700 ||| DT
number  ||| S:8700 E:8707 ||| NN
of  ||| S:8707 E:8718 ||| IN
recent  ||| S:8718 E:8725 ||| JJ
trials  ||| S:8725 E:8732 ||| NNS
have  ||| S:8732 E:8737 ||| VBP
suggested  ||| S:8737 E:8747 ||| VBN
that  ||| S:8747 E:8752 ||| IN
higher  ||| S:8752 E:8759 ||| JJR
risk  ||| S:8759 E:8764 ||| NN
patients  ||| S:8764 E:8773 ||| NNS
with  ||| S:8773 E:8786 ||| IN
non-ST  ||| S:8786 E:8793 ||| FW
elevation  ||| S:8793 E:8803 ||| FW
acute  ||| S:8803 E:8809 ||| FW
coronary  ||| S:8809 E:8818 ||| FW
syndromes  ||| S:8818 E:8828 ||| FW
fair  ||| S:8828 E:8833 ||| JJ
better  ||| S:8833 E:8840 ||| JJR
when  ||| S:8840 E:8853 ||| WRB
an  ||| S:8853 E:8856 ||| DT
early  ||| S:8856 E:8862 ||| JJ
invasive  ||| S:8862 E:8871 ||| JJ
strategy  ||| S:8871 E:8880 ||| NN
is  ||| S:8880 E:8883 ||| VBZ
applied  ||| S:8883 E:8891 ||| VBN
[  ||| S:8891 E:8893 ||| -LRB-
12  ||| S:8893 E:8896 ||| CD
13  ||| S:8896 E:8899 ||| CD
14  ||| S:8899 E:8902 ||| CD
]  ||| S:8902 E:8904 ||| -RRB-
and  ||| S:8904 E:8908 ||| CC
it  ||| S:8908 E:8919 ||| PRP
is  ||| S:8919 E:8922 ||| VBZ
not  ||| S:8922 E:8926 ||| RB
uncommon  ||| S:8926 E:8935 ||| JJ
for  ||| S:8935 E:8939 ||| IN
patients  ||| S:8939 E:8948 ||| NNS
to  ||| S:8948 E:8951 ||| TO
be  ||| S:8951 E:8954 ||| VB
treated  ||| S:8954 E:8962 ||| VBN
in  ||| S:8962 E:8965 ||| IN
this  ||| S:8965 E:8970 ||| DT
fashion ||| S:8970 E:8977 ||| NN
.  ||| S:8977 E:8987 ||| .
Second ||| S:8987 E:8993 ||| LS
,  ||| S:8993 E:8995 ||| ,
patients  ||| S:8995 E:9004 ||| NNS
with  ||| S:9004 E:9009 ||| IN
Q-wave  ||| S:9009 E:9016 ||| JJ
myocardial  ||| S:9016 E:9027 ||| JJ
infarction  ||| S:9027 E:9038 ||| NN
were  ||| S:9038 E:9043 ||| VBD
not  ||| S:9043 E:9055 ||| RB
eligible  ||| S:9055 E:9064 ||| JJ
for  ||| S:9064 E:9068 ||| IN
enrollment  ||| S:9068 E:9079 ||| NN
because  ||| S:9079 E:9087 ||| IN
it  ||| S:9087 E:9090 ||| PRP
was  ||| S:9090 E:9094 ||| VBD
felt  ||| S:9094 E:9099 ||| VBN
that  ||| S:9099 E:9104 ||| IN
statins  ||| S:9104 E:9120 ||| NNS
would  ||| S:9120 E:9126 ||| MD
not  ||| S:9126 E:9130 ||| RB
influence  ||| S:9130 E:9140 ||| VB
the  ||| S:9140 E:9144 ||| DT
development  ||| S:9144 E:9156 ||| NN
of  ||| S:9156 E:9159 ||| IN
important  ||| S:9159 E:9169 ||| JJ
prognostic  ||| S:9169 E:9188 ||| NNS
determinants  ||| S:9188 E:9201 ||| VBP
such  ||| S:9201 E:9206 ||| JJ
as  ||| S:9206 E:9209 ||| IN
left  ||| S:9209 E:9214 ||| VBN
ventricular  ||| S:9214 E:9226 ||| JJ
systolic  ||| S:9226 E:9235 ||| JJ
dysfunction ||| S:9235 E:9246 ||| NN
,  ||| S:9246 E:9256 ||| ,
ventricular  ||| S:9256 E:9268 ||| JJ
arrhythmias  ||| S:9268 E:9280 ||| NN
or  ||| S:9280 E:9283 ||| CC
mechanical  ||| S:9283 E:9294 ||| JJ
complications  ||| S:9294 E:9308 ||| NNS
[  ||| S:9308 E:9310 ||| -LRB-
5  ||| S:9310 E:9312 ||| LS
]  ||| S:9312 E:9314 ||| -RRB-
.  ||| S:9314 E:9324 ||| .
Nevertheless ||| S:9324 E:9336 ||| RB
,  ||| S:9336 E:9338 ||| ,
patients  ||| S:9338 E:9347 ||| NNS
who  ||| S:9347 E:9351 ||| WP
develop  ||| S:9351 E:9359 ||| VBP
electrocardiographic  ||| S:9359 E:9388 ||| JJ
Q-waves  ||| S:9388 E:9396 ||| NNS
represent  ||| S:9396 E:9406 ||| VBP
a  ||| S:9406 E:9408 ||| DT
substantial  ||| S:9408 E:9420 ||| JJ
proportion  ||| S:9420 E:9431 ||| NN
of  ||| S:9431 E:9434 ||| IN
all  ||| S:9434 E:9438 ||| DT
patients  ||| S:9438 E:9455 ||| NNS
with  ||| S:9455 E:9460 ||| IN
myocardial  ||| S:9460 E:9471 ||| JJ
infarction ||| S:9471 E:9481 ||| NN
.  ||| S:9481 E:9483 ||| .
While  ||| S:9483 E:9489 ||| IN
their  ||| S:9489 E:9495 ||| PRP$
short-term  ||| S:9495 E:9506 ||| JJ
risk  ||| S:9506 E:9519 ||| NN
following  ||| S:9519 E:9529 ||| VBG
hospital  ||| S:9529 E:9538 ||| NN
discharge  ||| S:9538 E:9548 ||| NN
is  ||| S:9548 E:9551 ||| VBZ
lower  ||| S:9551 E:9557 ||| RBR
relative  ||| S:9557 E:9566 ||| JJ
to  ||| S:9566 E:9569 ||| TO
those  ||| S:9569 E:9583 ||| DT
with  ||| S:9583 E:9588 ||| IN
a  ||| S:9588 E:9590 ||| DT
non-Q-wave  ||| S:9590 E:9601 ||| JJ
myocardial  ||| S:9601 E:9612 ||| JJ
infarction ||| S:9612 E:9622 ||| NN
,  ||| S:9622 E:9624 ||| ,
it  ||| S:9624 E:9627 ||| PRP
is  ||| S:9627 E:9630 ||| VBZ
still  ||| S:9630 E:9636 ||| RB
much  ||| S:9636 E:9649 ||| RB
greater  ||| S:9649 E:9657 ||| JJR
than  ||| S:9657 E:9662 ||| IN
in  ||| S:9662 E:9665 ||| IN
patients  ||| S:9665 E:9674 ||| NNS
with  ||| S:9674 E:9679 ||| IN
stable  ||| S:9679 E:9686 ||| JJ
coronary  ||| S:9686 E:9695 ||| JJ
disease ||| S:9695 E:9702 ||| NN
,  ||| S:9702 E:9704 ||| ,
and  ||| S:9704 E:9716 ||| CC
the  ||| S:9716 E:9720 ||| DT
need  ||| S:9720 E:9725 ||| NN
for  ||| S:9725 E:9729 ||| IN
secondary  ||| S:9729 E:9739 ||| JJ
prevention  ||| S:9739 E:9750 ||| NN
in  ||| S:9750 E:9753 ||| IN
this  ||| S:9753 E:9758 ||| DT
population  ||| S:9758 E:9769 ||| NN
is  ||| S:9769 E:9780 ||| VBZ
equally  ||| S:9780 E:9788 ||| RB
important ||| S:9788 E:9797 ||| JJ
.  ||| S:9797 E:9799 ||| .
Third ||| S:9799 E:9804 ||| JJ
,  ||| S:9804 E:9806 ||| ,
despite  ||| S:9806 E:9814 ||| IN
the  ||| S:9814 E:9818 ||| DT
high  ||| S:9818 E:9823 ||| JJ
risk  ||| S:9823 E:9828 ||| NN
nature  ||| S:9828 E:9835 ||| NN
of  ||| S:9835 E:9846 ||| IN
enrolled  ||| S:9846 E:9855 ||| JJ
patients  ||| S:9855 E:9864 ||| NNS
( ||| S:9864 E:9865 ||| -LRB-
ie ||| S:9865 E:9867 ||| UH
,  ||| S:9867 E:9869 ||| ,
electrocardiogram  ||| S:9869 E:9887 ||| NNS
[ ||| S:9887 E:9888 ||| -LRB-
ECG ||| S:9888 E:9891 ||| NNP
]  ||| S:9891 E:9893 ||| -RRB-
changes  ||| S:9893 E:9909 ||| NNS
and ||| S:9909 E:9912 ||| CC
/ ||| S:9912 E:9913 ||| NNP
or  ||| S:9913 E:9916 ||| CC
other  ||| S:9916 E:9922 ||| JJ
objective  ||| S:9922 E:9932 ||| NN
evidence  ||| S:9932 E:9941 ||| NN
of  ||| S:9941 E:9944 ||| IN
ischemia ||| S:9944 E:9952 ||| CD
) ||| S:9952 E:9953 ||| -RRB-
,  ||| S:9953 E:9955 ||| ,
the  ||| S:9955 E:9959 ||| DT
rate  ||| S:9959 E:9964 ||| NN
of  ||| S:9964 E:9975 ||| IN
platelet  ||| S:9975 E:9984 ||| FW
glycoprotein  ||| S:9984 E:9997 ||| FW
IIb ||| S:9997 E:10000 ||| FW
/ ||| S:10000 E:10001 ||| FW
IIIa  ||| S:10001 E:10006 ||| FW
inhibitor  ||| S:10006 E:10016 ||| FW
utilization  ||| S:10016 E:10028 ||| NN
was  ||| S:10028 E:10040 ||| VBD
quite  ||| S:10040 E:10046 ||| RB
low  ||| S:10046 E:10050 ||| JJ
( ||| S:10050 E:10051 ||| -LRB-
1.1 ||| S:10051 E:10054 ||| CD
% ||| S:10054 E:10055 ||| NN
) ||| S:10055 E:10056 ||| -RRB-
.  ||| S:10056 E:10058 ||| .
Such  ||| S:10058 E:10063 ||| JJ
therapy  ||| S:10063 E:10071 ||| NN
appears  ||| S:10071 E:10079 ||| VBZ
to  ||| S:10079 E:10082 ||| TO
be  ||| S:10082 E:10085 ||| VB
cost  ||| S:10085 E:10090 ||| VBN
effective  ||| S:10090 E:10108 ||| JJ
[  ||| S:10108 E:10110 ||| -LRB-
15  ||| S:10110 E:10113 ||| CD
16  ||| S:10113 E:10116 ||| CD
]  ||| S:10116 E:10118 ||| -RRB-
,  ||| S:10118 E:10120 ||| ,
especially  ||| S:10120 E:10131 ||| RB
among  ||| S:10131 E:10137 ||| IN
high  ||| S:10137 E:10142 ||| JJ
risk  ||| S:10142 E:10147 ||| NN
patients  ||| S:10147 E:10156 ||| NNS
and  ||| S:10156 E:10160 ||| CC
is  ||| S:10160 E:10171 ||| VBZ
recommended  ||| S:10171 E:10183 ||| VBN
under  ||| S:10183 E:10189 ||| IN
current  ||| S:10189 E:10197 ||| JJ
American  ||| S:10197 E:10206 ||| NNP
College  ||| S:10206 E:10214 ||| NNP
of  ||| S:10214 E:10225 ||| IN
Cardiology ||| S:10225 E:10235 ||| NNP
/ ||| S:10235 E:10236 ||| NNP
American  ||| S:10236 E:10245 ||| NNP
Heart  ||| S:10245 E:10251 ||| NNP
Association  ||| S:10251 E:10263 ||| NNP
guidelines  ||| S:10263 E:10274 ||| NNS
[  ||| S:10274 E:10276 ||| -LRB-
17  ||| S:10276 E:10279 ||| CD
]  ||| S:10279 E:10281 ||| -RRB-
.  ||| S:10281 E:10291 ||| .
Fourth ||| S:10291 E:10297 ||| JJ
,  ||| S:10297 E:10299 ||| ,
it  ||| S:10299 E:10302 ||| PRP
may  ||| S:10302 E:10306 ||| MD
not  ||| S:10306 E:10310 ||| RB
be  ||| S:10310 E:10313 ||| VB
possible  ||| S:10313 E:10322 ||| JJ
to  ||| S:10322 E:10325 ||| TO
ascertain  ||| S:10325 E:10335 ||| VB
whether  ||| S:10335 E:10343 ||| IN
these  ||| S:10343 E:10357 ||| DT
findings  ||| S:10357 E:10366 ||| NNS
apply  ||| S:10366 E:10372 ||| VBP
to  ||| S:10372 E:10375 ||| TO
all  ||| S:10375 E:10379 ||| DT
patients  ||| S:10379 E:10388 ||| NNS
with  ||| S:10388 E:10393 ||| IN
recent  ||| S:10393 E:10400 ||| JJ
acute  ||| S:10400 E:10406 ||| JJ
coronary  ||| S:10406 E:10423 ||| NNS
syndromes  ||| S:10423 E:10433 ||| VBP
regardless  ||| S:10433 E:10444 ||| RB
of  ||| S:10444 E:10447 ||| IN
baseline  ||| S:10447 E:10456 ||| JJ
lipid  ||| S:10456 E:10462 ||| NN
levels ||| S:10462 E:10468 ||| NNS
.  ||| S:10468 E:10470 ||| .
The  ||| S:10470 E:10474 ||| DT
small  ||| S:10474 E:10488 ||| JJ
difference  ||| S:10488 E:10499 ||| NN
in  ||| S:10499 E:10502 ||| IN
number  ||| S:10502 E:10509 ||| NN
of  ||| S:10509 E:10512 ||| IN
primary  ||| S:10512 E:10520 ||| JJ
endpoint  ||| S:10520 E:10529 ||| JJ
events  ||| S:10529 E:10536 ||| NNS
between  ||| S:10536 E:10552 ||| IN
atorvastatin  ||| S:10552 E:10565 ||| NN
and  ||| S:10565 E:10569 ||| CC
placebo  ||| S:10569 E:10577 ||| JJ
groups  ||| S:10577 E:10584 ||| NNS
make  ||| S:10584 E:10589 ||| VBP
it  ||| S:10589 E:10592 ||| PRP
difficult  ||| S:10592 E:10602 ||| JJ
to  ||| S:10602 E:10613 ||| TO
dissect  ||| S:10613 E:10621 ||| VB
the  ||| S:10621 E:10625 ||| DT
relationship  ||| S:10625 E:10638 ||| NN
between  ||| S:10638 E:10646 ||| IN
baseline  ||| S:10646 E:10655 ||| JJ
lipid  ||| S:10655 E:10661 ||| NN
levels  ||| S:10661 E:10668 ||| NNS
and  ||| S:10668 E:10680 ||| CC
treatment  ||| S:10680 E:10690 ||| NN
effect  ||| S:10690 E:10697 ||| NN
further ||| S:10697 E:10704 ||| RBR
.  ||| S:10704 E:10706 ||| .
Consequently ||| S:10706 E:10718 ||| RB
,  ||| S:10718 E:10720 ||| ,
it  ||| S:10720 E:10723 ||| PRP
remains  ||| S:10723 E:10739 ||| VBZ
uncertain  ||| S:10739 E:10749 ||| JJ
whether  ||| S:10749 E:10757 ||| IN
one  ||| S:10757 E:10761 ||| PRP
can  ||| S:10761 E:10765 ||| MD
extrapolate  ||| S:10765 E:10777 ||| VB
the  ||| S:10777 E:10781 ||| DT
MIRACL  ||| S:10781 E:10788 ||| NNP
trial  ||| S:10788 E:10802 ||| NN
results  ||| S:10802 E:10810 ||| NNS
to  ||| S:10810 E:10813 ||| TO
those  ||| S:10813 E:10819 ||| DT
who  ||| S:10819 E:10823 ||| WP
undergo  ||| S:10823 E:10831 ||| VBP
coronary  ||| S:10831 E:10840 ||| JJ
revascularization  ||| S:10840 E:10866 ||| NNS
shortly  ||| S:10866 E:10874 ||| RB
before  ||| S:10874 E:10881 ||| RB
or  ||| S:10881 E:10884 ||| CC
after  ||| S:10884 E:10890 ||| IN
a  ||| S:10890 E:10892 ||| DT
coronary  ||| S:10892 E:10901 ||| JJ
event ||| S:10901 E:10906 ||| NN
,  ||| S:10906 E:10908 ||| ,
who  ||| S:10908 E:10912 ||| WP
present  ||| S:10912 E:10920 ||| VBP
with  ||| S:10920 E:10933 ||| IN
a  ||| S:10933 E:10935 ||| DT
Q-wave  ||| S:10935 E:10942 ||| JJ
myocardial  ||| S:10942 E:10953 ||| JJ
infarction ||| S:10953 E:10963 ||| NN
,  ||| S:10963 E:10965 ||| ,
who  ||| S:10965 E:10969 ||| WP
are  ||| S:10969 E:10973 ||| VBP
treated  ||| S:10973 E:10981 ||| VBN
with  ||| S:10981 E:10994 ||| IN
platelet  ||| S:10994 E:11003 ||| FW
glycoprotein  ||| S:11003 E:11016 ||| FW
IIb ||| S:11016 E:11019 ||| FW
/ ||| S:11019 E:11020 ||| FW
IIIa  ||| S:11020 E:11025 ||| FW
inhibitors ||| S:11025 E:11035 ||| FW
,  ||| S:11035 E:11037 ||| ,
or  ||| S:11037 E:11040 ||| CC
who  ||| S:11040 E:11044 ||| WP
have  ||| S:11044 E:11057 ||| VBP
relatively  ||| S:11057 E:11068 ||| RB
low  ||| S:11068 E:11072 ||| JJ
admission  ||| S:11072 E:11082 ||| NN
LDL  ||| S:11082 E:11086 ||| NNP
cholesterol  ||| S:11086 E:11098 ||| NN
levels ||| S:11098 E:11104 ||| NNS
.  ||| S:11104 E:11128 ||| .
Time  ||| S:11128 E:11133 ||| NN
to  ||| S:11133 E:11136 ||| TO
change  ||| S:11136 E:11143 ||| VB
current  ||| S:11143 E:11151 ||| JJ
practice  ||| S:11151 E:11168 ||| NN
Although  ||| S:11168 E:11177 ||| IN
MIRACL  ||| S:11177 E:11184 ||| NNP
and  ||| S:11184 E:11188 ||| CC
the  ||| S:11188 E:11192 ||| DT
two  ||| S:11192 E:11196 ||| CD
aforementioned  ||| S:11196 E:11211 ||| JJ
cohort  ||| S:11211 E:11226 ||| JJ
studies  ||| S:11226 E:11234 ||| NNS
suggest  ||| S:11234 E:11242 ||| VBP
that  ||| S:11242 E:11247 ||| IN
lipid-lowering  ||| S:11247 E:11262 ||| JJ
agents  ||| S:11262 E:11269 ||| NNS
exert  ||| S:11269 E:11275 ||| VBP
short-term  ||| S:11275 E:11294 ||| JJ
clinical  ||| S:11294 E:11303 ||| JJ
benefits  ||| S:11303 E:11312 ||| NNS
when  ||| S:11312 E:11317 ||| WRB
initiated  ||| S:11317 E:11327 ||| VBN
soon  ||| S:11327 E:11332 ||| RB
after  ||| S:11332 E:11338 ||| IN
an  ||| S:11338 E:11341 ||| DT
acute  ||| S:11341 E:11355 ||| JJ
coronary  ||| S:11355 E:11364 ||| JJ
syndrome ||| S:11364 E:11372 ||| NN
,  ||| S:11372 E:11374 ||| ,
this  ||| S:11374 E:11379 ||| DT
remains  ||| S:11379 E:11387 ||| VBZ
an  ||| S:11387 E:11390 ||| DT
open  ||| S:11390 E:11395 ||| JJ
question ||| S:11395 E:11403 ||| NN
.  ||| S:11403 E:11405 ||| .
Even  ||| S:11405 E:11410 ||| RB
if  ||| S:11410 E:11421 ||| IN
these  ||| S:11421 E:11427 ||| DT
findings  ||| S:11427 E:11436 ||| NNS
are  ||| S:11436 E:11440 ||| VBP
not  ||| S:11440 E:11444 ||| RB
confirmed  ||| S:11444 E:11454 ||| VBN
after  ||| S:11454 E:11460 ||| IN
further  ||| S:11460 E:11468 ||| JJ
study ||| S:11468 E:11473 ||| NN
,  ||| S:11473 E:11475 ||| ,
one  ||| S:11475 E:11487 ||| PRP
could  ||| S:11487 E:11493 ||| MD
still  ||| S:11493 E:11499 ||| RB
make  ||| S:11499 E:11504 ||| VB
a  ||| S:11504 E:11506 ||| DT
compelling  ||| S:11506 E:11517 ||| JJ
argument  ||| S:11517 E:11526 ||| NN
that  ||| S:11526 E:11531 ||| IN
lipid-lowering  ||| S:11531 E:11554 ||| JJ
therapy  ||| S:11554 E:11562 ||| NN
( ||| S:11562 E:11563 ||| -LRB-
barring  ||| S:11563 E:11571 ||| FW
contraindications ||| S:11571 E:11588 ||| FW
)  ||| S:11588 E:11590 ||| -RRB-
should  ||| S:11590 E:11597 ||| MD
be  ||| S:11597 E:11600 ||| VB
initiated  ||| S:11600 E:11618 ||| VBN
early  ||| S:11618 E:11624 ||| JJ
and  ||| S:11624 E:11628 ||| CC
universally  ||| S:11628 E:11640 ||| RB
in  ||| S:11640 E:11643 ||| IN
patients  ||| S:11643 E:11652 ||| NNS
who  ||| S:11652 E:11656 ||| WP
present  ||| S:11656 E:11664 ||| VBP
with  ||| S:11664 E:11669 ||| IN
an  ||| S:11669 E:11672 ||| DT
acute  ||| S:11672 E:11686 ||| JJ
coronary  ||| S:11686 E:11695 ||| JJ
syndrome ||| S:11695 E:11703 ||| NN
:  ||| S:11703 E:11705 ||| :
First ||| S:11705 E:11710 ||| NNP
,  ||| S:11710 E:11712 ||| ,
the  ||| S:11712 E:11716 ||| DT
long-term  ||| S:11716 E:11726 ||| JJ
safety  ||| S:11726 E:11733 ||| NN
and  ||| S:11733 E:11745 ||| CC
effectiveness  ||| S:11745 E:11759 ||| NN
of  ||| S:11759 E:11762 ||| IN
statins  ||| S:11762 E:11770 ||| NN
for  ||| S:11770 E:11774 ||| IN
the  ||| S:11774 E:11778 ||| DT
secondary  ||| S:11778 E:11788 ||| JJ
prevention  ||| S:11788 E:11799 ||| NN
of  ||| S:11799 E:11811 ||| IN
stable  ||| S:11811 E:11818 ||| JJ
coronary  ||| S:11818 E:11827 ||| JJ
disease  ||| S:11827 E:11835 ||| NN
is  ||| S:11835 E:11846 ||| VBZ
well-established  ||| S:11846 E:11863 ||| JJ
[  ||| S:11863 E:11865 ||| -LRB-
1  ||| S:11865 E:11867 ||| CD
2  ||| S:11867 E:11869 ||| CD
3  ||| S:11869 E:11871 ||| CD
]  ||| S:11871 E:11873 ||| -RRB-
;  ||| S:11873 E:11875 ||| :
Second ||| S:11875 E:11881 ||| LS
,  ||| S:11881 E:11883 ||| ,
as  ||| S:11883 E:11886 ||| RB
evidenced  ||| S:11886 E:11896 ||| VBN
by  ||| S:11896 E:11907 ||| IN
MIRACL ||| S:11907 E:11913 ||| NNP
,  ||| S:11913 E:11915 ||| ,
these  ||| S:11915 E:11921 ||| DT
agents  ||| S:11921 E:11928 ||| NNS
are  ||| S:11928 E:11932 ||| VBP
safe  ||| S:11932 E:11937 ||| JJ
when  ||| S:11937 E:11942 ||| WRB
initiated  ||| S:11942 E:11952 ||| VBN
at  ||| S:11952 E:11955 ||| IN
the  ||| S:11955 E:11959 ||| DT
time  ||| S:11959 E:11964 ||| NN
of  ||| S:11964 E:11975 ||| IN
hospitalization  ||| S:11975 E:11991 ||| NN
for  ||| S:11991 E:11995 ||| IN
an  ||| S:11995 E:11998 ||| DT
acute  ||| S:11998 E:12004 ||| JJ
coronary  ||| S:12004 E:12013 ||| JJ
syndrome ||| S:12013 E:12021 ||| NN
;  ||| S:12021 E:12023 ||| :
Third ||| S:12023 E:12028 ||| LS
,  ||| S:12028 E:12030 ||| ,
the  ||| S:12030 E:12042 ||| DT
in-hospital  ||| S:12042 E:12054 ||| JJ
initiation  ||| S:12054 E:12065 ||| NN
of  ||| S:12065 E:12068 ||| IN
lipid-lowering  ||| S:12068 E:12083 ||| JJ
therapy  ||| S:12083 E:12091 ||| NN
appears  ||| S:12091 E:12099 ||| VBZ
to  ||| S:12099 E:12110 ||| TO
promote  ||| S:12110 E:12118 ||| VB
greater  ||| S:12118 E:12126 ||| JJR
long-term  ||| S:12126 E:12136 ||| JJ
utilization  ||| S:12136 E:12148 ||| NN
of  ||| S:12148 E:12151 ||| IN
these  ||| S:12151 E:12157 ||| DT
agents  ||| S:12157 E:12164 ||| NNS
[  ||| S:12164 E:12166 ||| -LRB-
18  ||| S:12166 E:12177 ||| CD
19  ||| S:12177 E:12180 ||| CD
20  ||| S:12180 E:12183 ||| CD
21  ||| S:12183 E:12186 ||| CD
]  ||| S:12186 E:12188 ||| -RRB-
.  ||| S:12188 E:12190 ||| .
Finally ||| S:12190 E:12197 ||| RB
,  ||| S:12197 E:12199 ||| ,
although  ||| S:12199 E:12208 ||| IN
lipid  ||| S:12208 E:12214 ||| JJ
levels  ||| S:12214 E:12221 ||| NNS
may  ||| S:12221 E:12225 ||| MD
be  ||| S:12225 E:12236 ||| VB
unreliable  ||| S:12236 E:12247 ||| VBN
in  ||| S:12247 E:12250 ||| IN
the  ||| S:12250 E:12254 ||| DT
setting  ||| S:12254 E:12262 ||| NN
of  ||| S:12262 E:12265 ||| IN
an  ||| S:12265 E:12268 ||| DT
acute  ||| S:12268 E:12274 ||| JJ
coronary  ||| S:12274 E:12283 ||| JJ
syndrome  ||| S:12283 E:12300 ||| NN
( ||| S:12300 E:12301 ||| -LRB-
excepting  ||| S:12301 E:12311 ||| JJ
total  ||| S:12311 E:12317 ||| NN
: ||| S:12317 E:12318 ||| :
HDL  ||| S:12318 E:12322 ||| NNP
and  ||| S:12322 E:12326 ||| CC
LDL ||| S:12326 E:12329 ||| NNP
: ||| S:12329 E:12330 ||| :
HDL  ||| S:12330 E:12334 ||| NNP
cholesterol  ||| S:12334 E:12346 ||| NN
ratios  ||| S:12346 E:12353 ||| NNS
[  ||| S:12353 E:12355 ||| -LRB-
22  ||| S:12355 E:12358 ||| CD
]  ||| S:12358 E:12368 ||| CD
)  ||| S:12368 E:12370 ||| -RRB-
the  ||| S:12370 E:12374 ||| DT
overwhelming  ||| S:12374 E:12387 ||| JJ
majority  ||| S:12387 E:12396 ||| NN
of  ||| S:12396 E:12399 ||| IN
patients  ||| S:12399 E:12408 ||| NNS
with  ||| S:12408 E:12413 ||| IN
coronary  ||| S:12413 E:12430 ||| JJ
disease  ||| S:12430 E:12438 ||| NN
will  ||| S:12438 E:12443 ||| MD
ultimately  ||| S:12443 E:12454 ||| RB
require  ||| S:12454 E:12462 ||| VB
both  ||| S:12462 E:12467 ||| DT
pharmacologic  ||| S:12467 E:12481 ||| NN
and  ||| S:12481 E:12493 ||| CC
non-pharmacologic  ||| S:12493 E:12511 ||| JJ
lipid-lowering  ||| S:12511 E:12526 ||| JJ
interventions  ||| S:12526 E:12540 ||| NNS
to  ||| S:12540 E:12543 ||| TO
attain  ||| S:12543 E:12558 ||| VB
recommended  ||| S:12558 E:12570 ||| VBN
cholesterol  ||| S:12570 E:12582 ||| NN
targets  ||| S:12582 E:12590 ||| NNS
[  ||| S:12590 E:12592 ||| -LRB-
23  ||| S:12592 E:12595 ||| CD
24  ||| S:12595 E:12598 ||| CD
25  ||| S:12598 E:12601 ||| CD
]  ||| S:12601 E:12603 ||| -RRB-
;  ||| S:12603 E:12605 ||| :
newer  ||| S:12605 E:12619 ||| JJR
guidelines  ||| S:12619 E:12630 ||| NNS
are  ||| S:12630 E:12634 ||| VBP
even  ||| S:12634 E:12639 ||| RB
more  ||| S:12639 E:12644 ||| RBR
stringent  ||| S:12644 E:12654 ||| JJ
[  ||| S:12654 E:12656 ||| -LRB-
26  ||| S:12656 E:12659 ||| CD
]  ||| S:12659 E:12661 ||| -RRB-
.  ||| S:12661 E:12663 ||| .
Furthermore ||| S:12663 E:12674 ||| RB
,  ||| S:12674 E:12684 ||| ,
data  ||| S:12684 E:12689 ||| NNS
from  ||| S:12689 E:12694 ||| IN
the  ||| S:12694 E:12698 ||| DT
recently  ||| S:12698 E:12707 ||| RB
presented  ||| S:12707 E:12717 ||| VBN
Heart  ||| S:12717 E:12723 ||| NNP
Protection  ||| S:12723 E:12734 ||| NNP
Study  ||| S:12734 E:12748 ||| NNP
suggest  ||| S:12748 E:12756 ||| VBP
that  ||| S:12756 E:12761 ||| IN
clinical  ||| S:12761 E:12770 ||| JJ
benefits  ||| S:12770 E:12779 ||| NNS
may  ||| S:12779 E:12783 ||| MD
accrue  ||| S:12783 E:12790 ||| VB
independent  ||| S:12790 E:12802 ||| JJ
of  ||| S:12802 E:12813 ||| IN
baseline  ||| S:12813 E:12822 ||| JJ
cholesterol  ||| S:12822 E:12834 ||| NN
level  ||| S:12834 E:12840 ||| NN
[  ||| S:12840 E:12842 ||| -LRB-
4  ||| S:12842 E:12844 ||| LS
]  ||| S:12844 E:12846 ||| -RRB-
.  ||| S:12846 E:12848 ||| .
Thus ||| S:12848 E:12852 ||| RB
,  ||| S:12852 E:12854 ||| ,
to  ||| S:12854 E:12857 ||| TO
withhold  ||| S:12857 E:12874 ||| VB
lipid-lowering  ||| S:12874 E:12889 ||| JJ
therapy  ||| S:12889 E:12897 ||| NN
from  ||| S:12897 E:12902 ||| IN
patients  ||| S:12902 E:12911 ||| NNS
who  ||| S:12911 E:12915 ||| WP
present  ||| S:12915 E:12923 ||| VBP
with  ||| S:12923 E:12928 ||| IN
an  ||| S:12928 E:12939 ||| DT
acute  ||| S:12939 E:12945 ||| JJ
coronary  ||| S:12945 E:12954 ||| JJ
syndrome  ||| S:12954 E:12963 ||| NN
would  ||| S:12963 E:12969 ||| MD
be  ||| S:12969 E:12972 ||| VB
to  ||| S:12972 E:12975 ||| TO
accept  ||| S:12975 E:12982 ||| VB
the  ||| S:12982 E:12986 ||| DT
status  ||| S:12986 E:12993 ||| FW
quo ||| S:12993 E:12996 ||| FW
,  ||| S:12996 E:13006 ||| ,
and  ||| S:13006 E:13010 ||| CC
to  ||| S:13010 E:13013 ||| TO
date  ||| S:13013 E:13018 ||| VB
our  ||| S:13018 E:13022 ||| PRP$
efforts  ||| S:13022 E:13030 ||| NNS
at  ||| S:13030 E:13033 ||| IN
cholesterol  ||| S:13033 E:13045 ||| NN
lowering  ||| S:13045 E:13054 ||| VBG
in  ||| S:13054 E:13057 ||| IN
the  ||| S:13057 E:13069 ||| DT
secondary  ||| S:13069 E:13079 ||| JJ
prevention  ||| S:13079 E:13090 ||| NN
setting  ||| S:13090 E:13098 ||| NNS
have  ||| S:13098 E:13103 ||| VBP
been  ||| S:13103 E:13108 ||| VBN
dismal  ||| S:13108 E:13115 ||| JJ
[  ||| S:13115 E:13117 ||| -LRB-
27  ||| S:13117 E:13120 ||| CD
28  ||| S:13120 E:13123 ||| CD
]  ||| S:13123 E:13133 ||| -RRB-
.  ||| S:13133 E:13157 ||| .
More  ||| S:13157 E:13162 ||| RBR
MIRACLes  ||| S:13162 E:13171 ||| JJ
ahead ||| S:13171 E:13176 ||| RB
?  ||| S:13176 E:13186 ||| .
The  ||| S:13186 E:13190 ||| DT
ascertainment  ||| S:13190 E:13204 ||| NN
and  ||| S:13204 E:13208 ||| CC
quantification  ||| S:13208 E:13223 ||| NN
of  ||| S:13223 E:13226 ||| IN
any  ||| S:13226 E:13230 ||| DT
incremental  ||| S:13230 E:13250 ||| JJ
benefit  ||| S:13250 E:13258 ||| NN
conferred  ||| S:13258 E:13268 ||| NN
by  ||| S:13268 E:13271 ||| IN
statin  ||| S:13271 E:13278 ||| JJ
therapy  ||| S:13278 E:13286 ||| NN
initiated  ||| S:13286 E:13296 ||| VBD
early  ||| S:13296 E:13302 ||| RB
after  ||| S:13302 E:13316 ||| IN
an  ||| S:13316 E:13319 ||| DT
acute  ||| S:13319 E:13325 ||| JJ
coronary  ||| S:13325 E:13334 ||| JJ
syndrome  ||| S:13334 E:13343 ||| NN
will  ||| S:13343 E:13348 ||| MD
require  ||| S:13348 E:13356 ||| VB
confirmation ||| S:13356 E:13368 ||| NN
.  ||| S:13368 E:13370 ||| .
There  ||| S:13370 E:13384 ||| EX
is  ||| S:13384 E:13387 ||| VBZ
currently  ||| S:13387 E:13397 ||| RB
only  ||| S:13397 E:13402 ||| RB
one  ||| S:13402 E:13406 ||| CD
ongoing  ||| S:13406 E:13414 ||| JJ
randomized  ||| S:13414 E:13425 ||| JJ
placebo-controlled  ||| S:13425 E:13452 ||| JJ
trial  ||| S:13452 E:13458 ||| NN
of  ||| S:13458 E:13461 ||| IN
early  ||| S:13461 E:13467 ||| JJ
versus  ||| S:13467 E:13474 ||| NNS
delayed  ||| S:13474 E:13482 ||| VBN
statin  ||| S:13482 E:13489 ||| JJ
therapy  ||| S:13489 E:13497 ||| NN
in  ||| S:13497 E:13500 ||| IN
this  ||| S:13500 E:13513 ||| DT
setting ||| S:13513 E:13520 ||| NN
,  ||| S:13520 E:13522 ||| ,
A-2-Z  ||| S:13522 E:13528 ||| NNP
( ||| S:13528 E:13529 ||| -LRB-
Aggrastat  ||| S:13529 E:13539 ||| NNP
to  ||| S:13539 E:13542 ||| TO
Zocor ||| S:13542 E:13547 ||| NNP
,  ||| S:13547 E:13549 ||| ,
Merck ||| S:13549 E:13554 ||| NNP
)  ||| S:13554 E:13556 ||| -RRB-
[  ||| S:13556 E:13558 ||| -LRB-
29  ||| S:13558 E:13561 ||| CD
]  ||| S:13561 E:13563 ||| -RRB-
.  ||| S:13563 E:13565 ||| .
The  ||| S:13565 E:13577 ||| DT
A-2-Z  ||| S:13577 E:13583 ||| JJ
study  ||| S:13583 E:13589 ||| NN
is  ||| S:13589 E:13592 ||| VBZ
evaluating  ||| S:13592 E:13603 ||| VBG
the  ||| S:13603 E:13607 ||| DT
efficacy  ||| S:13607 E:13616 ||| NN
of  ||| S:13616 E:13619 ||| IN
early  ||| S:13619 E:13625 ||| JJ
treatment  ||| S:13625 E:13643 ||| NN
with  ||| S:13643 E:13648 ||| IN
simvastatin  ||| S:13648 E:13660 ||| NN
in  ||| S:13660 E:13663 ||| IN
4,500  ||| S:13663 E:13669 ||| CD
patients  ||| S:13669 E:13678 ||| NNS
following  ||| S:13678 E:13688 ||| VBG
an  ||| S:13688 E:13691 ||| DT
episode  ||| S:13691 E:13699 ||| NN
of  ||| S:13699 E:13710 ||| IN
unstable  ||| S:13710 E:13719 ||| JJ
angina  ||| S:13719 E:13726 ||| NN
or  ||| S:13726 E:13729 ||| CC
a  ||| S:13729 E:13731 ||| DT
non-Q  ||| S:13731 E:13737 ||| JJ
wave  ||| S:13737 E:13742 ||| NN
myocardial  ||| S:13742 E:13753 ||| NN
infarction ||| S:13753 E:13763 ||| NN
.  ||| S:13763 E:13765 ||| .
In  ||| S:13765 E:13776 ||| IN
the  ||| S:13776 E:13780 ||| DT
first  ||| S:13780 E:13786 ||| JJ
four  ||| S:13786 E:13791 ||| CD
months ||| S:13791 E:13797 ||| NNS
,  ||| S:13797 E:13799 ||| ,
patients  ||| S:13799 E:13808 ||| NNS
will  ||| S:13808 E:13813 ||| MD
be  ||| S:13813 E:13816 ||| VB
randomized  ||| S:13816 E:13827 ||| VBN
to  ||| S:13827 E:13838 ||| TO
simvastatin  ||| S:13838 E:13850 ||| CD
40  ||| S:13850 E:13853 ||| CD
mg  ||| S:13853 E:13856 ||| CD
daily  ||| S:13856 E:13862 ||| JJ
or  ||| S:13862 E:13865 ||| CC
placebo ||| S:13865 E:13872 ||| NN
.  ||| S:13872 E:13874 ||| .
Thereafter ||| S:13874 E:13884 ||| RB
,  ||| S:13884 E:13886 ||| ,
those  ||| S:13886 E:13900 ||| DT
patients  ||| S:13900 E:13909 ||| NNS
treated  ||| S:13909 E:13917 ||| VBN
with  ||| S:13917 E:13922 ||| IN
simvastatin  ||| S:13922 E:13934 ||| NN
in  ||| S:13934 E:13937 ||| IN
the  ||| S:13937 E:13941 ||| DT
first  ||| S:13941 E:13947 ||| JJ
phase  ||| S:13947 E:13953 ||| NN
will  ||| S:13953 E:13966 ||| MD
receive  ||| S:13966 E:13974 ||| VB
80  ||| S:13974 E:13977 ||| CD
mg  ||| S:13977 E:13980 ||| NN
of  ||| S:13980 E:13983 ||| IN
simvastatin  ||| S:13983 E:13995 ||| JJ
daily  ||| S:13995 E:14001 ||| JJ
and  ||| S:14001 E:14005 ||| CC
those  ||| S:14005 E:14011 ||| DT
treated  ||| S:14011 E:14019 ||| VBN
with  ||| S:14019 E:14032 ||| IN
placebo ||| S:14032 E:14039 ||| NN
,  ||| S:14039 E:14041 ||| ,
40  ||| S:14041 E:14044 ||| CD
mg  ||| S:14044 E:14047 ||| NN
of  ||| S:14047 E:14050 ||| IN
simvastatin  ||| S:14050 E:14062 ||| JJ
daily ||| S:14062 E:14067 ||| JJ
.  ||| S:14067 E:14069 ||| .
The  ||| S:14069 E:14073 ||| DT
primary  ||| S:14073 E:14081 ||| JJ
composite  ||| S:14081 E:14099 ||| JJ
endpoint  ||| S:14099 E:14108 ||| NN
is  ||| S:14108 E:14111 ||| VBZ
the  ||| S:14111 E:14115 ||| DT
occurrence  ||| S:14115 E:14126 ||| NN
of  ||| S:14126 E:14129 ||| IN
cardiovascular  ||| S:14129 E:14144 ||| JJ
death ||| S:14144 E:14149 ||| NN
,  ||| S:14149 E:14159 ||| ,
non-fatal  ||| S:14159 E:14169 ||| JJ
myocardial  ||| S:14169 E:14180 ||| JJ
infarction ||| S:14180 E:14190 ||| NN
,  ||| S:14190 E:14192 ||| ,
or  ||| S:14192 E:14195 ||| CC
rehospitalization  ||| S:14195 E:14213 ||| NN
for  ||| S:14213 E:14225 ||| IN
an  ||| S:14225 E:14228 ||| DT
acute  ||| S:14228 E:14234 ||| JJ
coronary  ||| S:14234 E:14243 ||| JJ
syndrome  ||| S:14243 E:14252 ||| NN
( ||| S:14252 E:14253 ||| -LRB-
ACS ||| S:14253 E:14256 ||| NNP
)  ||| S:14256 E:14258 ||| -RRB-
at  ||| S:14258 E:14261 ||| IN
one  ||| S:14261 E:14265 ||| CD
year ||| S:14265 E:14269 ||| NN
.  ||| S:14269 E:14271 ||| .
If  ||| S:14271 E:14274 ||| IN
A-2-Z  ||| S:14274 E:14288 ||| NNP
demonstrates  ||| S:14288 E:14301 ||| VBZ
significant  ||| S:14301 E:14313 ||| JJ
reductions  ||| S:14313 E:14324 ||| NNS
in  ||| S:14324 E:14327 ||| IN
the  ||| S:14327 E:14331 ||| DT
incidence  ||| S:14331 E:14341 ||| NN
of  ||| S:14341 E:14352 ||| IN
adverse  ||| S:14352 E:14360 ||| JJ
events  ||| S:14360 E:14367 ||| NNS
during  ||| S:14367 E:14374 ||| IN
the  ||| S:14374 E:14378 ||| DT
first  ||| S:14378 E:14384 ||| JJ
four  ||| S:14384 E:14389 ||| CD
months ||| S:14389 E:14395 ||| NNS
,  ||| S:14395 E:14397 ||| ,
it  ||| S:14397 E:14400 ||| PRP
would  ||| S:14400 E:14414 ||| MD
suggest  ||| S:14414 E:14422 ||| VB
an  ||| S:14422 E:14425 ||| DT
incremental  ||| S:14425 E:14437 ||| JJ
clinical  ||| S:14437 E:14446 ||| JJ
benefit  ||| S:14446 E:14454 ||| NN
from  ||| S:14454 E:14459 ||| IN
initiating  ||| S:14459 E:14478 ||| VBG
these  ||| S:14478 E:14484 ||| DT
agents  ||| S:14484 E:14491 ||| NNS
early  ||| S:14491 E:14497 ||| RB
after  ||| S:14497 E:14503 ||| IN
an  ||| S:14503 E:14506 ||| DT
acute  ||| S:14506 E:14512 ||| JJ
coronary  ||| S:14512 E:14521 ||| JJ
syndrome ||| S:14521 E:14529 ||| NN
.  ||| S:14529 E:14531 ||| .
If  ||| S:14531 E:14542 ||| IN
benefits  ||| S:14542 E:14551 ||| NNS
accrue ||| S:14551 E:14557 ||| NN
,  ||| S:14557 E:14559 ||| ,
but  ||| S:14559 E:14563 ||| CC
do  ||| S:14563 E:14566 ||| VBP
so  ||| S:14566 E:14569 ||| RB
later  ||| S:14569 E:14575 ||| RB
during  ||| S:14575 E:14582 ||| IN
follow  ||| S:14582 E:14589 ||| VB
up ||| S:14589 E:14591 ||| RP
,  ||| S:14591 E:14593 ||| ,
it  ||| S:14593 E:14596 ||| PRP
would  ||| S:14596 E:14610 ||| MD
be  ||| S:14610 E:14613 ||| VB
difficult  ||| S:14613 E:14623 ||| JJ
to  ||| S:14623 E:14626 ||| TO
discriminate  ||| S:14626 E:14639 ||| VB
between  ||| S:14639 E:14647 ||| IN
the  ||| S:14647 E:14651 ||| DT
effects  ||| S:14651 E:14659 ||| NNS
of  ||| S:14659 E:14662 ||| IN
more  ||| S:14662 E:14675 ||| RBR
aggressive  ||| S:14675 E:14686 ||| JJ
vs.  ||| S:14686 E:14690 ||| NN
earlier  ||| S:14690 E:14698 ||| RBR
lipid  ||| S:14698 E:14704 ||| JJ
lowering  ||| S:14704 E:14713 ||| JJ
therapy ||| S:14713 E:14720 ||| NN
.  ||| S:14720 E:14730 ||| .
The  ||| S:14730 E:14734 ||| DT
Pravastatin  ||| S:14734 E:14746 ||| NNP
or  ||| S:14746 E:14749 ||| CC
Atorvastatin  ||| S:14749 E:14762 ||| NNP
Evaluation  ||| S:14762 E:14773 ||| NNP
and  ||| S:14773 E:14777 ||| CC
Infection  ||| S:14777 E:14795 ||| NNP
Therapy  ||| S:14795 E:14803 ||| NNP
( ||| S:14803 E:14804 ||| -LRB-
PROVE  ||| S:14804 E:14810 ||| NNP
IT ||| S:14810 E:14812 ||| NNP
)  ||| S:14812 E:14814 ||| -RRB-
trial  ||| S:14814 E:14820 ||| NN
is  ||| S:14820 E:14823 ||| VBZ
looking  ||| S:14823 E:14831 ||| VBG
at  ||| S:14831 E:14834 ||| IN
4,000  ||| S:14834 E:14840 ||| CD
patients  ||| S:14840 E:14857 ||| NNS
within  ||| S:14857 E:14864 ||| IN
10  ||| S:14864 E:14867 ||| CD
days  ||| S:14867 E:14872 ||| NNS
of  ||| S:14872 E:14875 ||| IN
an  ||| S:14875 E:14878 ||| DT
acute  ||| S:14878 E:14884 ||| JJ
coronary  ||| S:14884 E:14893 ||| JJ
syndrome  ||| S:14893 E:14902 ||| NN
and  ||| S:14902 E:14914 ||| CC
randomizing  ||| S:14914 E:14926 ||| VBD
them  ||| S:14926 E:14931 ||| PRP
to  ||| S:14931 E:14934 ||| TO
either  ||| S:14934 E:14941 ||| DT
pravastatin  ||| S:14941 E:14953 ||| JJ
40  ||| S:14953 E:14956 ||| CD
mg  ||| S:14956 E:14959 ||| NNS
or  ||| S:14959 E:14970 ||| CC
atorvastatin  ||| S:14970 E:14983 ||| CD
80  ||| S:14983 E:14986 ||| CD
mg  ||| S:14986 E:14989 ||| CD
daily  ||| S:14989 E:14995 ||| JJ
[  ||| S:14995 E:14997 ||| -LRB-
29  ||| S:14997 E:15000 ||| CD
]  ||| S:15000 E:15002 ||| -RRB-
.  ||| S:15002 E:15004 ||| .
Patients  ||| S:15004 E:15013 ||| NNS
will  ||| S:15013 E:15018 ||| MD
be  ||| S:15018 E:15021 ||| VB
observed  ||| S:15021 E:15038 ||| VBN
over  ||| S:15038 E:15043 ||| RP
at  ||| S:15043 E:15046 ||| IN
least  ||| S:15046 E:15052 ||| JJS
1.5  ||| S:15052 E:15056 ||| CD
years  ||| S:15056 E:15062 ||| NNS
for  ||| S:15062 E:15066 ||| IN
the  ||| S:15066 E:15070 ||| DT
occurrence  ||| S:15070 E:15081 ||| NN
of  ||| S:15081 E:15084 ||| IN
myocardial  ||| S:15084 E:15103 ||| JJ
infarction  ||| S:15103 E:15114 ||| NN
or  ||| S:15114 E:15117 ||| CC
other  ||| S:15117 E:15123 ||| JJ
cardiovascular  ||| S:15123 E:15138 ||| JJ
events ||| S:15138 E:15144 ||| NNS
.  ||| S:15144 E:15146 ||| .
Unlike ||| S:15146 E:15152 ||| NNP
,  ||| S:15152 E:15154 ||| ,
MIRACL  ||| S:15154 E:15169 ||| NNP
and  ||| S:15169 E:15173 ||| CC
the  ||| S:15173 E:15177 ||| DT
A-2-Z  ||| S:15177 E:15183 ||| CD
trials ||| S:15183 E:15189 ||| NNS
,  ||| S:15189 E:15191 ||| ,
this  ||| S:15191 E:15196 ||| DT
study  ||| S:15196 E:15202 ||| NN
will  ||| S:15202 E:15207 ||| MD
not  ||| S:15207 E:15211 ||| RB
assess  ||| S:15211 E:15218 ||| VB
the  ||| S:15218 E:15230 ||| DT
efficacy  ||| S:15230 E:15239 ||| NN
of  ||| S:15239 E:15242 ||| IN
early  ||| S:15242 E:15248 ||| JJ
statin  ||| S:15248 E:15255 ||| JJ
therapy  ||| S:15255 E:15263 ||| NN
after  ||| S:15263 E:15269 ||| IN
an  ||| S:15269 E:15272 ||| DT
acute  ||| S:15272 E:15278 ||| JJ
coronary  ||| S:15278 E:15295 ||| JJ
syndrome ||| S:15295 E:15303 ||| NN
;  ||| S:15303 E:15305 ||| :
rather ||| S:15305 E:15311 ||| RB
,  ||| S:15311 E:15313 ||| ,
it  ||| S:15313 E:15316 ||| PRP
will  ||| S:15316 E:15321 ||| MD
examine  ||| S:15321 E:15329 ||| VB
the  ||| S:15329 E:15333 ||| DT
role  ||| S:15333 E:15338 ||| NN
of  ||| S:15338 E:15350 ||| IN
more  ||| S:15350 E:15355 ||| JJR
vs.  ||| S:15355 E:15368 ||| IN
less  ||| S:15368 E:15373 ||| RBR
aggressive  ||| S:15373 E:15384 ||| JJ
lipid-lowering  ||| S:15384 E:15399 ||| NN
in  ||| S:15399 E:15410 ||| IN
this  ||| S:15410 E:15415 ||| DT
setting ||| S:15415 E:15422 ||| NN
.  ||| S:15422 E:15432 ||| .
In  ||| S:15432 E:15435 ||| IN
2002 ||| S:15435 E:15439 ||| CD
,  ||| S:15439 E:15441 ||| ,
many  ||| S:15441 E:15446 ||| JJ
would  ||| S:15446 E:15452 ||| MD
consider  ||| S:15452 E:15461 ||| VB
it  ||| S:15461 E:15464 ||| PRP
unethical  ||| S:15464 E:15474 ||| VBP
to  ||| S:15474 E:15477 ||| TO
withhold  ||| S:15477 E:15494 ||| VB
statins  ||| S:15494 E:15502 ||| VBN
from  ||| S:15502 E:15507 ||| IN
patients  ||| S:15507 E:15516 ||| NNS
with  ||| S:15516 E:15521 ||| IN
established  ||| S:15521 E:15533 ||| JJ
coronary  ||| S:15533 E:15542 ||| JJ
disease ||| S:15542 E:15549 ||| NN
.  ||| S:15549 E:15559 ||| .
This  ||| S:15559 E:15564 ||| DT
makes  ||| S:15564 E:15570 ||| VBZ
it  ||| S:15570 E:15573 ||| PRP
unlikely  ||| S:15573 E:15582 ||| RB
that  ||| S:15582 E:15587 ||| IN
additional  ||| S:15587 E:15598 ||| JJ
placebo-controlled  ||| S:15598 E:15625 ||| JJ
trials  ||| S:15625 E:15632 ||| NNS
will  ||| S:15632 E:15637 ||| MD
be  ||| S:15637 E:15640 ||| VB
carried  ||| S:15640 E:15648 ||| VBN
out  ||| S:15648 E:15652 ||| RP
in  ||| S:15652 E:15655 ||| IN
this  ||| S:15655 E:15660 ||| DT
area ||| S:15660 E:15664 ||| NN
.  ||| S:15664 E:15666 ||| .
Future  ||| S:15666 E:15673 ||| JJ
secondary  ||| S:15673 E:15691 ||| JJ
prevention  ||| S:15691 E:15702 ||| NN
studies  ||| S:15702 E:15710 ||| NNS
should  ||| S:15710 E:15717 ||| MD
look  ||| S:15717 E:15722 ||| VB
at  ||| S:15722 E:15725 ||| IN
patients  ||| S:15725 E:15734 ||| NNS
with  ||| S:15734 E:15739 ||| IN
stable  ||| S:15739 E:15755 ||| JJ
or  ||| S:15755 E:15758 ||| CC
unstable  ||| S:15758 E:15767 ||| JJ
disease  ||| S:15767 E:15775 ||| NN
and  ||| S:15775 E:15779 ||| CC
will  ||| S:15779 E:15784 ||| MD
need  ||| S:15784 E:15789 ||| VB
to  ||| S:15789 E:15800 ||| TO
address  ||| S:15800 E:15808 ||| VB
the  ||| S:15808 E:15812 ||| DT
comparative  ||| S:15812 E:15824 ||| JJ
efficacy  ||| S:15824 E:15833 ||| NN
of  ||| S:15833 E:15836 ||| IN
different  ||| S:15836 E:15846 ||| JJ
statins  ||| S:15846 E:15854 ||| NNS
( ||| S:15854 E:15855 ||| -LRB-
or  ||| S:15855 E:15866 ||| CC
newer  ||| S:15866 E:15872 ||| JJR
agents ||| S:15872 E:15878 ||| NNS
) ||| S:15878 E:15879 ||| -RRB-
,  ||| S:15879 E:15881 ||| ,
assess  ||| S:15881 E:15888 ||| VB
the  ||| S:15888 E:15892 ||| DT
incremental  ||| S:15892 E:15904 ||| JJ
benefit  ||| S:15904 E:15912 ||| NN
of  ||| S:15912 E:15923 ||| IN
combination  ||| S:15923 E:15935 ||| NN
therapy  ||| S:15935 E:15943 ||| NN
[  ||| S:15943 E:15945 ||| -LRB-
30  ||| S:15945 E:15948 ||| CD
]  ||| S:15948 E:15950 ||| -RRB-
and  ||| S:15950 E:15954 ||| CC
determine  ||| S:15954 E:15964 ||| VB
whether  ||| S:15964 E:15972 ||| IN
there  ||| S:15972 E:15978 ||| EX
is  ||| S:15978 E:15981 ||| VBZ
a  ||| S:15981 E:15991 ||| DT
serum  ||| S:15991 E:15997 ||| JJ
cholesterol  ||| S:15997 E:16009 ||| NN
' ||| S:16009 E:16010 ||| POS
floor ||| S:16010 E:16015 ||| NN
'  ||| S:16015 E:16017 ||| ''
below  ||| S:16017 E:16023 ||| IN
which  ||| S:16023 E:16029 ||| WDT
reductions  ||| S:16029 E:16040 ||| NNS
are  ||| S:16040 E:16052 ||| VBP
unlikely  ||| S:16052 E:16061 ||| JJ
to  ||| S:16061 E:16064 ||| TO
provide  ||| S:16064 E:16072 ||| VB
further  ||| S:16072 E:16080 ||| RBR
clinical  ||| S:16080 E:16089 ||| JJ
benefit ||| S:16089 E:16096 ||| NN
.  ||| S:16096 E:16120 ||| .
Competing  ||| S:16120 E:16130 ||| VBG
interests  ||| S:16130 E:16148 ||| NNS
Dr  ||| S:16148 E:16151 ||| NNP
Aronow  ||| S:16151 E:16158 ||| NNP
has  ||| S:16158 E:16162 ||| VBZ
received  ||| S:16162 E:16171 ||| VBN
honoraria  ||| S:16171 E:16181 ||| VBN
as  ||| S:16181 E:16184 ||| IN
a  ||| S:16184 E:16186 ||| DT
speaker  ||| S:16186 E:16194 ||| NN
and  ||| S:16194 E:16206 ||| CC
advisory  ||| S:16206 E:16215 ||| JJ
board  ||| S:16215 E:16221 ||| NN
member  ||| S:16221 E:16228 ||| NN
for  ||| S:16228 E:16232 ||| IN
Pfizer  ||| S:16232 E:16239 ||| NNP
and  ||| S:16239 E:16243 ||| CC
as  ||| S:16243 E:16246 ||| IN
a  ||| S:16246 E:16248 ||| DT
speaker  ||| S:16248 E:16256 ||| NN
for  ||| S:16256 E:16268 ||| IN
Merck ||| S:16268 E:16273 ||| NNP
.  ||| S:16273 E:16297 ||| .
Abbreviations  ||| S:16297 E:16319 ||| NNP
HMG  ||| S:16319 E:16323 ||| NNP
CoA  ||| S:16323 E:16327 ||| NNP
=  ||| S:16327 E:16329 ||| SYM
3-Hydroxy-3-methylgluatryl  ||| S:16329 E:16356 ||| FW
coenzyme  ||| S:16356 E:16365 ||| FW
A ||| S:16365 E:16366 ||| NNP
;  ||| S:16366 E:16368 ||| :
MIRACL  ||| S:16368 E:16383 ||| NNP
=  ||| S:16383 E:16385 ||| NNP
Myocardial  ||| S:16385 E:16396 ||| NNP
Ischemia  ||| S:16396 E:16405 ||| NNP
Reduction  ||| S:16405 E:16415 ||| NNP
with  ||| S:16415 E:16420 ||| IN
Aggressive  ||| S:16420 E:16431 ||| NNP
Cholesterol  ||| S:16431 E:16451 ||| NNP
Lowering ||| S:16451 E:16459 ||| NNP
;  ||| S:16459 E:16461 ||| :
LDL  ||| S:16461 E:16465 ||| NNP
=  ||| S:16465 E:16467 ||| SYM
low  ||| S:16467 E:16471 ||| JJ
density  ||| S:16471 E:16479 ||| NN
lipoprotein ||| S:16479 E:16490 ||| NNS
;  ||| S:16490 E:16492 ||| :
RR  ||| S:16492 E:16495 ||| NNP
=  ||| S:16495 E:16497 ||| SYM
relative  ||| S:16497 E:16514 ||| JJ
risk ||| S:16514 E:16518 ||| NN
;  ||| S:16518 E:16520 ||| :
CI  ||| S:16520 E:16523 ||| NNP
=  ||| S:16523 E:16525 ||| SYM
confidence  ||| S:16525 E:16536 ||| NN
interval ||| S:16536 E:16544 ||| NNS
;  ||| S:16544 E:16546 ||| :
HDL  ||| S:16546 E:16550 ||| NNP
=  ||| S:16550 E:16552 ||| SYM
high  ||| S:16552 E:16557 ||| JJ
density  ||| S:16557 E:16573 ||| NN
lipoprotein ||| S:16573 E:16584 ||| NNS
;  ||| S:16584 E:16586 ||| :
PTCA  ||| S:16586 E:16591 ||| NNP
=  ||| S:16591 E:16593 ||| SYM
percutaneous  ||| S:16593 E:16606 ||| FW
transluminal  ||| S:16606 E:16619 ||| FW
coronary  ||| S:16619 E:16636 ||| FW
angioplasty ||| S:16636 E:16647 ||| FW
;  ||| S:16647 E:16649 ||| :
CABG  ||| S:16649 E:16654 ||| NNP
=  ||| S:16654 E:16656 ||| SYM
coronary  ||| S:16656 E:16665 ||| FW
artery  ||| S:16665 E:16672 ||| FW
bypass  ||| S:16672 E:16679 ||| FW
graft ||| S:16679 E:16684 ||| FW
;  ||| S:16684 E:16686 ||| :
ECG  ||| S:16686 E:16690 ||| NNP
=  ||| S:16690 E:16700 ||| SYM
electrocardiogram ||| S:16700 E:16717 ||| FW
;  ||| S:16717 E:16719 ||| :
A-2-Z  ||| S:16719 E:16725 ||| CD
=  ||| S:16725 E:16727 ||| SYM
Aggrastat  ||| S:16727 E:16737 ||| NNP
to  ||| S:16737 E:16740 ||| TO
Zocor ||| S:16740 E:16745 ||| NNP
;  ||| S:16745 E:16747 ||| :
ACS  ||| S:16747 E:16751 ||| NNP
=  ||| S:16751 E:16753 ||| SYM
acute  ||| S:16753 E:16767 ||| FW
coronary  ||| S:16767 E:16776 ||| FW
syndrome ||| S:16776 E:16784 ||| FW
;  ||| S:16784 E:16786 ||| :
PROVE  ||| S:16786 E:16792 ||| NNP
IT  ||| S:16792 E:16795 ||| NNP
=  ||| S:16795 E:16797 ||| NNP
Pravastatin  ||| S:16797 E:16809 ||| NNP
or  ||| S:16809 E:16812 ||| CC
Atorvastatin  ||| S:16812 E:16833 ||| NNP
Evaluation  ||| S:16833 E:16844 ||| NNP
and  ||| S:16844 E:16848 ||| CC
Infection  ||| S:16848 E:16858 ||| NNP
Therapy ||| S:16858 E:16865 ||| NNP
.  ||| S:16865 E:16882 ||| .
